Validated Method Development for the Quantification of Cinitapride and Pantoprazole by Spectrophotometry and RP-HPLC in Bulk and Oral Dosge form. by Hemalatha, P V
VALIDATED METHOD DEVELOPMENT FOR THE 
QUANTIFICATION OF CINITAPRIDE AND 
PANTOPRAZOLE BY SPECTROPHOTOMETRY  
AND RP-HPLC IN BULK AND ORAL DOSGE FORM 
 
A dissertation submitted to 
The Tamilnadu Dr. M.G.R. Medical University 
Chennai – 600 032. 
 
In partial fulfillment of the requirements 
for the award of the degree of  
 
MASTER OF PHARMACY 
IN 
PHARMACEUTICAL CHEMISTRY 
 
      Submitted by 
 
       Reg. No. 26108332 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
 
MAY 2012 
VALIDATED METHOD DEVELOPMENT FOR THE 
QUANTIFICATION OF CINITAPRIDE AND 
PANTOPRAZOLE BY SPECTROPHOTOMETRY  
AND RP-HPLC IN BULK AND ORAL DOSGE FORM 
 
A dissertation submitted to 
The Tamilnadu Dr. M.G.R. Medical University 
Chennai – 600 032. 
 
In partial fulfillment of the requirements 
for the award of the degree of  
 
MASTER OF PHARMACY 
IN 
PHARMACEUTICAL CHEMISTRY 
 
      Submitted by 
 
       Reg. No. 26108332 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
 
MAY 2012 
CERTIFICATE 
 
This is to certify that the dissertation entitled “VALIDATED METHOD 
DEVELOPMENT FOR THE QUANTIFICATION OF CINITAPRIDE AND 
PANTOPRAZOLE  BY SPECTROPHOTOMETRY AND RP-HPLC IN BULK 
AND ORAL DOSGE FORM’’ submitted by Reg. No. 26108332   in partial 
fulfillment of the requirements for the award of the degree of MASTER OF 
PHARMACY in PHARMACEUTICAL CHEMISTRY by The Tamilnadu 
Dr.M.G.R. Medical Univeristy is a bonafide work done by her during the academic 
year 2011-2012 at the Department of Pharmaceutical Chemistry, College of 
Pharmacy, Madras Medical College, Chennai – 600 003. 
                                                       
 
 
     
 
 Dr. A. JERAD SURESH, M.Pharm., Ph.D., 
                                                                                 Principal, College of Pharmacy, 
                                                             Professor  & HOD 
Dept. of Pharmaceutical Chemistry 
                                                                  College of Pharmacy 
                                                                          Madras Medical College, 
                                                                  Chennai – 600 003. 
   
CERTIFICATE 
 
This is to certify that the dissertation entitled “VALIDATED METHOD 
DEVELOPMENT FOR THE QUANTIFICATION OF CINITAPRIDE AND 
PANTOPRAZOLE  BY SPECTROPHOTOMETRY AND RP-HPLC IN BULK 
AND ORAL DOSGE FORM’’ submitted by Reg. No. 26108332                                   
in partial fulfillment of the requirements for the award of the degree of MASTER OF 
PHARMACY   in   PHARMACEUTICAL   CHEMISTRY    by   The    Tamilnadu  
Dr. M.G.R. Medical University is a bonafide work done by her during the academic year 
2011- 2012 under my guidance. 
 
 
 
 
 
 
 
Dr. (Mrs.) V. NIRAIMATHI, M.Pharm., Ph.D., 
                                                      Project Advisor, 
 Dept. of Pharmaceutical Chemistry, 
                                                                College of Pharmacy,  
                                                                      Madras Medical College, 
                                                              Chennai  600 003. 
 
ACKNOWLEDGEMENTS 
 
I, first and foremost express my revered regard and obeisance to the ALMIGHTY GOD 
with whose blessings I was able to complete my project work. 
I am grateful to express my sincere thanks to Dr. KANAGASABAI, M.D., Dean, 
Madras Medical College, for giving an opportunity to carry out my project work. 
It is my privilege to express a deep and heartfelt sense of gratitude and honorable regards 
to our respected, Dr. A. JERAD SURESH, M.PHARM., Ph.D., Principal, College of 
Pharmacy and Professor and Head, Department of Pharmaceutical Chemistry for his 
whole hearted support in rendering me all the facilities required for my project work. 
It is my utmost duty and privilege to express my heartfelt gratitude and sincere thanks to 
Dr. (MRS.) V. NIRAIMATHI, M.Pharm., Ph.D.,  Assistant Reader in Pharmacy, 
Department of Pharmaceutical Chemistry, for her active guidance, advise, help, support 
and encouragement. I am very much obliged for her perseverance, without which my 
project work would not have been completed. 
I thank Mrs. P.G.Sunitha, M.Pharm., Mrs. T.Saraswathi, M.Pharm., Mrs. 
R.Priyadarshini, M.Pharm., Mr. M.Satish, M.Pharm., Tutors in Pharmacy, 
Department of Pharmaceutical Chemistry for their kind help. 
I thank Mr. D.Siva Kumar, Mr. Baskaran and Mrs.R.Usha,  lab supervisors, 
Department of Pharmaceutical Chemistry for their kind help. 
I also thank Mrs. Maheshwari, Mrs. V. Booma and  Mrs. Murugeshwari,  lab 
technicians, Department of Pharmaceutical Chemistry for their kind help. 
I express my special thanks to my ever loving friends Mrs. D. Priya and Miss. A. 
Kalaimagal for their constant motivation and help. I also thank all other friends and the 
juniors of my department. 
Last but not the least, I would like to express my heartfelt thanks to my mother, my 
brothers and sister, my husband and my kids for extending their full support and 
help. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
                                           
S.No. TITLE Page No. 
1. INTRODUCTION 1 
2. DRUG PROFILE 18 
3. REVIEW OF LITERATURE 24 
4. AIM AND OBJECTIVE OF THE STUDY 34 
5. MATERIALS AND METHODS 
I. UV-SPECTROPHOTOMETRY 
Standard absorbance method                                                                                                               
Area Under Curve 
Derivative Spectrophotometry 
II. VISIBLE SPECTROPHOTOMETRY 
Colorimetry  
Diazotisation and coupling with EAA 
Diazotisation and coupling with AAC 
Colorimetry          
Oxidation and complexation with 1,10- Phenanthroline  
Oxidation and complexation with ammonium thiocyanate 
III. HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
36 
38 
44 
45 
45 
 
 
47 
48 
 
51 
52 
 
60 
6. RESULTS AND DISCUSSION 66 
7. SUMMARY & CONCLUSION 123 
8. REFERENCES 126 
LIST OF ABBREVIATIONS 
 
 
S.No ABBREVIATION EXPANSION 
1. CNP Cinitapride 
2. PNP Pantoprazole 
3. Avg. Average 
4. LOD Limit of Detection 
5. LOQ Limit of Quantification 
6. µg Microgram 
7. mg Milligram 
8. mL Millilitre 
9. R.S.D Relative standard deviation 
10. Rt Retention time 
11. Std. Standard 
12. SD Standard deviation 
13. UV Ultra-Violet Spectroscopy 
14. Wt. Weight 
15. HPLC High Performance Liquid Chromatography 
16. RP-HPLC Reverse phase High Performance Liquid 
Chromatography 
17. AAC Acetyl acetone 
18. EAA Ethyl acetoacetate 
19. ATC Ammonium thiocyanate 
20. Abs Absorbance 
21. Conc. Concentration 
22. 1,10-PHT 1,10- Phenanthroline 
 
 
 
 
 
Department of Pharmaceutical Chemistry Page 1 
 
INTRODUCTION 
            Analytical chemistry is the branch of chemical science which deals with the 
identification of components of a mixture by separating them and then analyzing 
how much percentage of each component is present in the mixture, in other words, it 
is a branch of chemistry dealing with any type of technique which may yield any sort 
of information about a chemical system occurring in nature or of artificial or 
synthetic origin.  
          Analytical chemistry involves two basic or major divisions. 
I. Qualitative analysis: 
           It involves the establishment of chemical composition of a material of natural 
or synthetic origin i.e., it deals with the identification of atoms, ions and 
molecules that make the material being analyzed. Two essential requirement 
of a qualitative analytical method  are 
           Specificity 
            Ability to detect the presence of an unknown element in the presence of other 
elements. Example: iron in presence of nickel, manganese, chromium etc. 
           Sensitivity  
 Smallest quantity of the element that can be detected by the given method. It 
is expressed in magnitudes of the order of 1mgm (one millionth part of a 
gram) 
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II. Quantitative analysis 
           It involves the estimation or determination of the amount of element  on 
molecule qualitatively detected present in the compound being analyzed. In 
addition to specificity and sensitivity quantitative analysis is characterized by 
accuracy.  
Significance of Analytical Chemistry 
 The identification of gases which was once considered as a single substance 
was of great significance in chemical analysis.  
 The chemical composition of a matter is determined. 
 Structure elucidation of a compound is possible. 
 Helps to analyze which component of a mixture or which part of the chemical 
structure was responsible for the reaction  
Significance of Pharmaceutical analysis  
     Structure elucidation of newly synthesized drug or isolated from natural 
origin.  
     Provides information on the identity, purity, content and stability of starting 
materials, excipients and active pharmaceutical ingredients. (Pharmaceutical 
analysis – Metrohm 2009) 
     Pharmacokinetic studies of drugs become easier  
     Studies involving metabolites of the drugs was possible  
     Impurity profiling of the drug  
     Stability indicating degradation studies  
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    Chiral separation of enantiomers and analyzing which enantiomer is 
responsible for  the bio activity 
 Bio analytical studies became simpler and easy to perform by the emergence  
of hyphenated analytical techniques  
   To check the purity of the raw material thus making cost effective synthesis  
of drugs. 
        Structure elucidation of proteins and creation of protein data bank. In  
medicine, analytical chemistry is the basis for clinical laboratory tests which 
help physicians diagnose disease and chart progress in recovery. 
     In Industry, analytical chemistry provides the means of testing raw materials 
and for assuring the quality of finished products whose chemical composition 
is critical. 
 Environmental quality is often evaluated by testing for suspected 
contaminants using the techniques of analytical chemistry (Anonymous 
www.acs-analytical.duq.edu/whatisanalyticalchem.html)  
 The recent developments of computer automation and information 
technologies have innervated analytical chemistry to initiate a number of new 
biological fields. For example, automated DNA sequencing machines were 
the basis to complete human genome projects leading to the birth of 
genomics. Protein identification and peptide sequencing by mass 
spectrometry opened a new field of proteomics.  
Analytical chemistry plays important role in quality control and quality 
assurance. It helps to analyze whether a given raw material or finished product is of 
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good acceptable quality (quality assurance) and to control the quality of the analyte 
up to the standard so that the raw material could be further taken in to the 
manufaturing process and the finished product could be let in to the market. 
Quality assurance is a wide-ranging concept covering all matters that individually or 
collectively influence the quality of a product. It is the totality of the arrangements 
made with the object of ensuring that pharmaceutical products are of the quality 
required for their intended use. Quality assurance therefore incorporates GMP  
Quality control, commonly shortened to QC refers to all those processes and 
procedures designed to ensure that the results of laboratory analysis are consistent, 
comparable, and accurate and within specified limits of precision. 
            Methods of analytical chemistry 
         The compound of interest is separated by precipitation or extraction or 
distillation. Further they are subjected to qualitative or quantitative analysis. 
  Qualitative analysis 
      Separated components treated with reagents that yield product that could be 
recognized by color, boiling point, melting point, solubility in a series of 
solvents, odour, optical activity and refractive index. 
  Quantitative analysis 
       The separated components is quantitatively analysed by gravimetric or titrimetry.  
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Quantitative Analytical Techniques  involve the following techniques (Willard, et 
al. 1986; Douglas, A. Skoog, et al.,2004;  P.D.Sethi, 2001)  
         The different classical methods are       
        Titrimetric methods: The volume of a solution containing sufficient reagent  
to react completely with the analyte is measured.  It include  acid – base,     
precipitation, redox, complexometric, diazotisation, aqueous           and non 
aqueous titrations which involve either  direct and indirect (back titration) 
methods 
 Gravimetric methods determine the mass of the analyte or some  compound 
chemically related to it by   weighing mass of the analyte after extraction, 
derivative separation, residue after ignition. 
Instrumental Methods 
 Spectrophotometric methods are based on measurement of the interaction 
between electromagnetic radiation and analyte. It includes  UV-Visible, Infra 
red, Raman, Mass, Nuclear magnetic resonance(NMR), fluorimetry, flame 
photometry, nephelo- turbidimetry. 
 Electro analytical methods involve the measurement of electrical properties  
such  as voltage, current, resistance etc.  It include potentiometry, 
conductometry, amperometry, electrogravimetry etc 
 Separation methods all types of chromatography like thin layer, paper, 
column, gas, High Performance Liquid and High Performance Thin Layer 
Chromatography. 
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  Miscellaneous methods include 
            thermal analysis(based on heat of reaction), kinetic techniques     
(based  on the kinetics of reactions of the analyte), enzyme assay 
  Hyphenated techniques includes the combination of the   above discussed 
methods like GC-MS (Gas chromatography – Mass spectrometry), LC-MS 
(Liquid chromatography – Mass spectrometry), GC-IR (Gas 
chromatography – Infrared spectroscopy), ICP-MS (Inductively coupled 
plasma–Mass spectrometry), LC-DAD-MS (Liquid chromatography – 
Diode Array Detector – Mass   spectrometry), LC-MS-MS (Liquid 
chromatography – Mass spectrometry – Mass     spectrometry).     
            Analytical Method Validation (Code Q2A- ICH Guidelines IP, 1996) 
         Method validation is the process to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. For pharmaceutical 
analytical methods guidelines from the United States Pharmacopeia (USP) 
International Conference on Harmonization (ICH), and Food and Drug 
Administration (FDA) provide a frame work for performing such validations.  
Types of Validation (Sethi, 2008) 
     Prospective validation  
            This is employed when historical data of the productis not available. Such   
validation is conducted prior torelease of eithr new product or product made 
under revised / new manufacturing process where revision may affect the 
product characters.  
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       Retrospective validation 
            This provides a review and evaluation of existing information for comparison  
when historical data is sufficient and readily available. Retrospective 
validation is  acceptable only when specific test results generated by reliable 
analytical method on number of samples are available to allow statistical 
analysis. 
     Concurrent validation 
                        This verifies the quality characteristics s of a particular batch and provides                      
assurance that the same quality would be attained again when subsequent 
batches are manufactured and analyzed under similar conditions  
            Reasons for Validation 
•       Enables scientiststo evaluate procedures for checking complaints and taking  
remedial measures. 
•       To provide high degree of confidence that the same level of quality is 
consistently   built in each unit of finished product from batch to batch. 
•       To take appropriate action, in case of non-compliance. 
•       Closer interaction with pharmacopoeial harmonization particularly with 
respect to determination of imprities and their limits. 
 Methods need to be validated or revalidated:  
 Before their introduction into routine use 
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  Whenever the conditions change for which the method has been validated. 
e.g., instruments with different characteristics. 
  Whenever the method is changed, and the change is outside the original scope 
of the method, the International Conference on Harmonization (ICH) of 
Technical Requirements for the Registration of Pharmaceuticals for human 
use has developed a consensus text on the validation of analytical procedures. 
The document includes definitions for eight validation characteristics which 
includes.  
 Linearity          
 Specificity 
 Accuracy 
 Precision 
 Repeatability 
 Intermediate precision 
 Reproducibility 
 Limit of detection 
 Limit of quantification 
 Range 
 Ruggedness 
 Robustness 
 
 
Department of Pharmaceutical Chemistry Page 9 
 
Linearity 
The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration of analytes in samples. Acceptability of 
linearity data is judged by the correlation coefficient and intercept of the linear 
regression line for the response versus concentration plot. The range of correlation 
coefficient should be NLT -1 and NMT +1. 
Specificity 
 It is the ability of the method to accurately measure the analyte response in the 
presence of all sample components like placebo formulation, synthesis intermediates, 
excipients, degradation products, process impurities etc., in comparison with the 
response of the standard analyte (or only the analyte). 
Accuracy 
           The accuracy of an analytical method is the extent to which test results 
generated by the method and the true value agree. Accuracy of the method is the 
closeness of the measured value to the true value. 
 Accuracy is calculated as the percentage of recovery by the assay of the 
known added amount of standard analyte in the previously analyzed sample (spiked 
sample), or as the difference between the mean and the accepted true value, together 
with confidence interval. Accuracy is usually performed in triplicate at three levels 
over a range of 50 to 150% of the target concentration.(Analytical chemistry 1996) 
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  Precision 
 It may be measure of either the degree of reproducibility, intermediate 
precision or repeatability of the analytical method under normal operating 
conditions.  It is usually expressed as SD (Co-efficient of variation) of a series of 
measurements. 
 Repeatability (intraday precision) refers to the use of analytical procedure 
within the laboratory over a short period of time using the same analyst with same 
instrument. 
 Reproducibility refers to the use of analytical procedure in different 
laboratories as in a collaborative study. 
Detection Limit (LOD) 
 It is the lowest amount of analyte in the sample that produces a response 
detectable above the noise level of the system, but not necessarily quantified as an 
exact value. Based on the standard deviation of the response and the slope the 
detection limit (LOD) may be expressed as  
 
3.3

 
Where,  
σ - standard deviation of the response,   
S – Slope of the calibration curve of the analyte. 
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Quantitation Limit (LOQ) 
  It is the lowest amount of analyte in the sample that can be determined with 
acceptable precision and accuracy under the stated experimental conditions. If not 
determined experimentally it can be calculated as the analyte concentration that gives 
S/N= 10 (Signal to Noise ratio). The quantitation limit is expressed as the 
concentration of analyte (eg : percentage parts per million) of the sample. 
                              	 
10 

 
Where, σ - standard deviation of the response, 
  S – Slope of the calibration curve (of the analyte) 
Range 
 Range of a method is the interval between the upper and the lower levels of 
analyte (including these concentrations) that have been demonstrated to be 
determined within a suitable level of precision, accuracy and linearity. 
Sensitivity 
 The sensitivity of an analytical method is the capability of the method to 
discriminate small differences in concentration or mass of the test analyte. In 
practical terms, sensitivity is the slope of the calibration curve that is obtained by 
plotting the response against the analyte concentration or mass. 
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Ruggedness 
            Ruggedness is a measure of reproducibility of test results under normal, 
expected operational conditions from laboratory to laboratory and from analyst to 
analyst. Ruggedness is determined by the analysis of aliquots from homogeneous 
lots in different laboratories. 
Robustness 
 Robustness tests examine the effect that operational parameters have on the 
analysis results. For the determination of a method’s robustness, a number of method 
parameters, for example, pH, flow rate, column temperature, injection volume, 
detection wavelength or mobile phase composition, are varied within a realistic 
range, and the quantitative influence of the variables is determined. If the influence 
of the parameter is within a previously specified tolerance, the parameter is said to be 
within the method’s robustness range.  
System suitability parameters for HPLC analysis: 
 The purpose of the system suitability test is to ensure that the complete testing 
system (including instrument, reagents, columns, analysts) is suitable for the 
intended application.  System suitability tests are an integral part of gas and liquid 
chromatographic methods. They are used to verify that the resolution and 
reproducibility of the chromatographic system are adequate for the analysis to be 
done. There are numerous guidelines which detail the expected limits for typical 
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chromatographic methods. In the current FDA guideline on “Validation of 
Chromatographic methods” the following acceptance limits are proposed as initial 
criteria. 
Capacity Factor (k') 
  
 It is the measure of a sample peak in the chromatogram being specific for a 
given compound, a parameter which specifies the delay of a substance to be 
separated. 
                                                    
 
                                                                        ′ 


 
Where,                    
tr = retention time from time of injection to time of elution of peak   maximum.               
to = void volume 
Resolution (Rs)  
 The resolution Rs is a function of column efficiency N and is specified to 
ensure that closely eluting compounds are resolved from each other to establish the 
general resolving power of the system and to ensure that internal standards are 
resolved from the drug.        
      
                
21
21 )(2
WW
ttR
+
−
=
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Where, 
    t1 and t2 = retention times of first and second adjacent bands. 
   W1 and W2 = width of peak 
Limit = Rs of >2 between the peak of interest and the closest potential interfering 
peak is desirable. 
 
 Tailing Factor (T) 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced.In 
some cases, values less than unity may be observed. As peak asymmetry increases, 
integration, and hence precision becomes less reliable. 
                                   
.

 
Where, 
W0.05 = width of peak at 5% height 
f      = Distance from the peak maximum to the leading edge of the peak, the distance 
being measured at a point 5% of the peak height from the baseline. 
Limit: ≤ 2 is preferable.  
Theoretical plates (N) 
 The number of theoretical plates, N is a measure of column efficiency. For 
Gaussian peaks, it is calculated by the equations. 
                                N = 16(t / w)2 (or)    N = 5.54(t / w1/2)2 
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Where, 
t = retention time of substance. 
w = width of the peak at its base, obtained by extrapolating the relatively      straight 
sides of the peak to the baseline. 
w1/2 = width of the peak at half height, obtained directly by electronic integrators. 
The value of ‘N’ depends upon the substance being chromatographed as well as the        
operating conditions such as mobile phase, temperature etc. 
The limits of system suitability are tabulated below (system stablility -online): 
 
 
 
 
 
 
 
STATISTICS IN ANALYTICAL CHEMISTRY 
 It is the science of making effective use of numerical data relating to groups of 
individuals or experiments.  It is the quantitative science, meaning that desired result 
is almost always numeric. 
S.No System suitability parameters Limits 
1. Capacity factor k’>2 
2. Injection Precision RSD<1% 
for n > 5 
3. Resolution Rs>2 
4. Tailing  factor T<2 
5. Theoretical plates N > 2000 
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 Quantitative results are obtained using devices or instruments that allow us to 
determine the concentration of a chemical in a sample from observable signal.  One 
of the use of statistics in analytical chemistry is to provide an estimate of the likely 
value of that error, in otherwords, to establish the uncertainty associated with the 
measurement. 
STATISTICAL PARAMETERS 
 The precision or reproducibility of the analytical method was 
determined by repeating the analysis and the following statistical parameters 
were calculated. 
Mean 
 The Mean or average is obtained by dividing the sum of observed 
values by the number of observations (n).  
                                               
n
X
x
∑
=
 
 Standard Deviation 
 Standard deviation (SD) is measure of data dispersion or variability.            
The standard deviation gives an idea of how close the entire set of data is to 
the average value. SD is also called root mean square deviation. 
∑ −−= 1/)( 2 nXXSD
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Relative Standard Deviation 
 The relative standard deviation (RSD) is also called co-efficient of 
variation. It is defined as  
XSDRSD /=
 
100% ×=
X
SDRSD
 
Regression Equation 
 A regression is a statistical analysis assessing the association between 
two variables. It is used to find the relationship between two variables. 
Regression equation                y = mx + c 
Where,  
m – the slope of regression line;  
c– the intercept point of regression line and the y axis 
Standard Error 
Standard error is a statistical term that measures the accuracy with which a 
sample represents a population. In statistics, a samplemean deviates from the 
actual mean of a population; this deviation is the standard error.  Standard 
error (SE) is given by       
                                          
n
SDSE =
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I.  CINITAPRIDE ( O’ Neil MJ
Cinitapride is available in the form of cinitapr
is a new gastro prokinetic agent. It is a substituted benzamide with 5
antagonist and agonist activity. It is chemically described as 4
cyclohexen-1-ylmethyl)
tartarate. 
EMPIRICAL FORMULA
MOLECULAR WEIGHT
STRUCTURE   
DESCRIPTION 
The tartarate salt of cinitapride is almost lemon yellow crystalline powder.It 
is freely soluble in methanol, soluble in water, ethanol, parti
insoluble in carbon tetra chloride, chloroform. 
 
DRUG PROFILE 
., 2007;  S. C. Sweetman 2002 ) 
ide  hydrogen  tart
-4-piperidinyl]-2-ethoxy-5-nitrobenzamide hydrogen L
  :    C25H36N40O10 
 :       552.58. 
 
Cinitapride 
ally soluble in acetone, 
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arate which 
-HT receptor 
-Amino-N-[1-(3-
-(+)-
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SOLUBILITY  
           Cinitaprde hydrogen tartarate is freely soluble in methanol, Ethanol, 
acetonitrile; soluble in water, 0.1N hydrochloric acid and in chloroform, practically 
insoluble acetone, ether and precipitates in 0.1N sodium hydroxide. 
MECHANISM OF ACTION 
           Cinitapride is a substituted benzamide gastroenteric prokinetic agent acting 
via complex, but synergistic effects on serotonergic 5-HT2 (inhibition) and 5-HT4 
(stimulation) receptor and dopaminergic D2 (inhibition) receptors in the neuronal 
synapses of the m yenteric plexus   
 INDICATIONS AND USAGE  
            Cinitapride is indicated for the treatment of gastrointestinal disorders     
associated with motility disturbances such as gastro esophageal reflux disease, non-
ulcer dyspepsia and delayed gastric emptying. 
             DOSAGE AND ADMINISTRATION 
 The usual daily dosage for adults is 1mg of Cinitapride orally thrice a day 15 
minutes before meals. The dose may be reduced, if required, depending on the 
patient’s age and symptoms at the discretion of the physician. 
 PHARMACOKINETICS 
  Pharmacokinetic studies in man following oral and intramuscular 
administration have been made using doses substantially higher than the therapeutic 
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dose due to the absence of a sufficiently sensitive analytical method for the detection 
of plasma concentrations following very low doses of cinitapride. The absorption of 
cinitapride (12mg) following oral administration was rapid, with peak levels being 
achieved 2 h after dosing; absorption following intramuscular administration (4mg) 
was even more rapid, with peak levels (50% more that oral levels) being achieved 1 
h after dosing.  
           CONTRAINDICATIONS 
  Cinitapride is contraindicated in patients with known hypersensitivity to 
cinitapride or any of the other constituents of the formulation. 
DRUG INTERACTIONS 
  Anticholinergic agents like atropine, scopolamine etc, may reduce the action 
of cinitapride. Cinitapride can enhance the effect of medicines that are used for the 
treatment of illnesses of the nervous system and for insomnia. Cinitapride can also 
alter the absorption of some medicines e.g. digoxin as it simulates gastric emptying. 
UNDESIRABLE EFFECTS 
  Cinitapride has usually been very well tolerated with the most common 
adverse events in clinical trials being drowsiness and diaorrhea. Extrapyramidal 
effects (involuntary muscular movements of the head, neck and tongue) have been 
reported occasionally. Very rarely, cutaneous reactions like eruptions, itching or 
angioedema and gynaecomastia have been reported. 
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OVERDOSAGE 
 The symptoms of overdose include drowsiness, confusion and extrapyramidal 
effects. Cinitapride does not cause QT prolongation. In case of excessive 
overdosage, the usual measures of gastric lavage and symptomatic therapy should be 
applied. The extrapyramidal effects should be treated with antiparkinsonians, 
anticholinergics or antihistaminics with anticholinergic properties. 
II. PANTOPRAZOLE SODIUM SESQUIHYDRATE (www.drugbank) 
 Pantoprazole is an irreversible proton pump inhibitor drug used for short-term 
treatment of erosion and ulceration of the esophagus caused by gastro esophageal 
reflux disease. .Like other drugs of its class, reduces gastric acid secretion by 
inhibition of portion on the parietal cells. Pantoprazole inhibits H+/K+ ATPase pump 
function thereby reducing gastric acid secretion. It also has a role in the eradication 
of H.pylori. Chemically, pantoprazole is 6-(difluoromethoxy)-2-{[(3,4-
dimethoxypyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole 
EMPIRICAL FORMULA:  
 Pantoprazole free base                      :  C16 H15 F2 N3 O4 S 
 Pantoprazole sodium sesquihydrate  :  C16 H14 F2 N3 O4 SNa. 1.5 H2O 
MOLECULAR WEIGHT: 
Pantoprazole free base                       :   383.37 g/mol 
Pantoprazole sodium sesquihydrate   :   432.38 g/mol 
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STRUCTURE 
                  Pantoprazole sodium sesquihydrate  
DESCRIPTION: 
            The sodium salt of pantoprazole is almost white to off
powder.It is freely soluble in methanol, soluble in water, ethanol, partially soluble in 
acetone, insoluble in carbon tetra chloride, chloroform. Because of gradual 
degradation of pantoprazole sodium during heating, the melting point cannot be 
determined 
MECHANISM OF ACTION
            Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in 
gastric acid production by forming a covalent bond to two sites of the (H+, K+)
ATPase enzyme system at the secretory surface of the 
effect is dose-related and leads to inhibition of both basal and stimulated gastric acid 
secretion irrespective of the stimulus. The binding to the (H+, K+)
a duration of antisecretory effect that persists long
 
 
 
 
-white, crystalline 
  
gastric parietal cell. This 
-ATPase results in 
er than 24 hours. 
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           PHARMACOKINETICS (Radhofer-Welte  S.,1999) 
Absorption                 :  Well absorbed; peak plasma concentrations: Approx 2-3 hr       
Oral bioavailability  : Approx 77% with enteric-coated formulation (does not vary 
after single or multiple doses).  
Distribution               : Protein-binding: 98%; volume of distribution: 11-24L. 
Metabolism        : Hepatic; mainly by cytochrome CYP2C19 and slightly by 
CYP2D6 and CYP2C0. 
INDICATIONS 
            Pantoprazole used for short-term treatment of erosion and ulceration of the 
esophagus caused by gastro- esophageal reflux disease. It is the drug of choice for 
the initial treatment of H.pylori along with other drugs.  
DRUG INTERACTIONS 
            Pantoprazole shows interactions: Indinavir, Enoxacin, Clopidogrel, 
Ketoconazole, Topotecan, Cefditoren, Itraconazole, Dasatinib. 
FOOD INTERACTIONS :   Take without regard to meal   
            INCOMPATIBILITY       :    Incompatible with midazolam and zinc. 
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REVIEW OF LITERATURE 
A review of literature was done for the past fifteen years to enumerate various 
methods available for the analysis of cinitapride and pantoprazole. In view of the 
literature cited for the quantification of cinitapride and pantoprazole in 
pharmaceutical dosage forms, there is no documentary evidence available. 
Pantoprazole and Cinitapride in combined dosage form 
Patel G.H., et al., (2011) developed HPTLC method for the estimation of 
pantoprazole and cinitapride in combined dosage forms. Chromatographic separation 
of the drugs was performed on aluminium plates precoated with silica gel 60 F254 as 
the stationary phase and the solvent system consisted of ethyl acetate: methanol 9: 
1(v/v). Densitometric evaluation of the separated zones was performed at 278 nm. 
 Paresh U. Patel., et al., (2011) developed first derivative spectrophotometric 
analytical method for the simultaneous estimation of pantoprazole and cinitapride in 
combined dosage form. The drugs obeyed the Beer’s law in the concentration range 
of 1-26 ug/mL. Zero crossing point of cinitapride was found to be 302 nm and zero 
crossing Point of Pantoprazole was 249 nm.  
CINITAPRIDE  
Alarcon de Lastra C., et al., (1998) studied the effects of cinitapride on gastric 
ulceration and secretion in rats. The study demonstrated a gastro protective nature of 
cinitapride not only through reduction of neutrophil toxicity but by an increased 
synthesis of free radical scavenging enzymes glutathione peroxidase. Further it 
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showed seratonergic dependent mechanism are also involved by 5-HT2 blockade and 
5-HT1 receptor activation . 
González Marti I., et al., (1998) determined cinitapride by differential pulse 
polarography and adsorptive stripping voltammetry (ASV) in Britton–Robinson 
buffer, with 3s detection limits of 1.3×10−8 and 8.4×10−10 M, respectively. ASV 
was applied for the determination of cinitapride in urine samples with an 
accumulation time of 65 s. A 3s detection limit was found to be 1.8×10−7 M with 
RSD of 1% was determined.  
Matias E Manzotti.,  et al., (2007)  determined the utility of prokinetic drugs 
 (cinitapride, cisapride) in improving symptoms and endoscopic lesions in patients 
with GERD esophagitis. They concluded that randomized controlled trials provided 
moderate-quality evidence that prokinetic drugs improve symptoms in patients with 
reflux esophagitis and low-quality evidence that they have an impact on endoscopic 
healing.  
Helena Marquez., et al., (2011) developed a UHPLC method for the assessment of 
the metabolic profile of cinitapride. Metabolites were generated from the incubation 
of cinitapride with human liver microsomes. Cinitapride and its metabolites were 
separated by reversed-phase mode using a formate aqueous solution (pH 6.5) and 
acetonitrile as the components of the mobile phase. Limits of detection are about 
0.03µmol/L, and repeatabilities were better than 0.06% for retention times and better 
than 3.5% for concentrations. The method was applied to characterize the in 
vitro cinitapride metabolism with human liver microsomes. 
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Marta Robert., et al., (2007) studied that the prokinetic cinitapride has no clinically 
relevant pharmacokinetic interaction and effect on QT during coadministration with 
ketoconazole. The safety and tolerability of the study treatments were also evaluated.  
Shikha Roy M.N., et al., (2008) determined free levels of cinitapride in human 
plasma by liquid chromatography- tandem mass spectrometry.  Risperidone was used 
as the internal standard. The method was developed by extracting the sample and 
analyzed by high performance liquid chromatography coupled to electrospray tandem 
mass spectrometry API-4000 (LC-MS/MS). The method allowed an appropriate 
characterization of the pharmacokinetic profile of cinitapride at the therapeutic dose. 
Thangabalan B.,  et al., (2010) validated extractive spectrophotometric estimation of 
cinitapride in pure and its solid dosage form. These methods  are  based  on  the 
formation of chloroform soluble ion-association complexes of cinitapride with 
bromocresol green and with bromothymol blue in potassium hydrogen phthalate 
buffer PH- 4.0 with absorption maximum at about 414 and 416nm for BCG and BTB 
respectively.  
Roy S.M.N., et al., (2010) developed RP-HPLC method for the determination of 
cinitapride under stress induced degradation studies.. The drug was subjected to all 
stress conditions such as reduction, oxidation acidic and alkaline medium. 
Acetonitrile and phosphate buffer, pH 6.7 in the ratio (70:30 v/v) was used as the 
mobile phase and cinitapride detected at 260nm. Glimepride was used as an internal 
standard. The drug was found to degrade extensively in reduction conditions and mild 
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degradation in the presence of in alkaline, acidic and oxidative condition but the drug 
was found to be stable under thermal stress. 
Syeda Humaire., et al., (2010) developed colorimetric method for the determination 
of cinitapride hydrogen tartarate in drug formulations. Six simple and sensitive 
spectrophotometric methods (A, B, C, D, E and F) have been developed for the 
quantitative estimation of cinitapride in bulk drug and pharmaceutical dosage forms. 
Method A and B is based on the oxidation followed by coupling reaction of 
cinitapride with 1, 10 phenanthroline and 2, 2’ bipyridyl in presence of ferric chloride 
to form orange‐red colored chromogens respectively. Methods are based on the 
diazotization of cinitapride with nitrous acid followed by its coupling in situ with N- 
(1-naphthyl) ethylenediamine dihydrochloride to form pinkish purple colored 
chromogen(C), with phloroglucinol to form orange colored chromogen (D), with 
diphenylamine to form pink colored chromogen (E) and with chromo tropic acid to 
form orange colored chromogen (F) respectively. 
Syeda Humaira et al., (2011) developed a validated RP-HPLC method to determine 
cinitapride hydrogen tartarate in solid oral dosage forms. Gradient elution technique 
with mobile phase consisting of 0.1% formic acid in water and acetonitrile and UV 
detection wavelength of 268nm was utilized. The developed method was validated for 
precision which includes system precision and method precision, accuracy and 
linearity studies in the concentration range of 5-100 µg/mL with correlation 
coefficient of 0.9987. The accuracy (recovery) was between 97.32 and 100.82%.  
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Thangabalan B., et al., (2011) analysed spectrophotometrically the amount of 
cinitapride in tablet dosage form using 2.0 M sodium benzoate solution as the 
hydrotropic solubilizing agent.. Cinitapride showed λ max at 395 nm obeyed Beers 
law at 10-80µg/mL. The results were validated statistically and by recovery studies. 
Suresh Ch.V., et al., (2011) developed a new visible spectrophotometric method for 
the determination of cinitapride in pharmaceutical dosage forms. They developed 
three methods involving charge transfer complex with chloranilic acid, oxidative 
coupling with MBTH and oxidation followed by complex formation with 1, 10 - 
phenanthroline in the ferric chloride. The complexes were found to show λ max at 
550, 420, and 510nm respectively. 
PANTOPRAZOLE  
Patricia Poole., (2001) compared pantoprazole with histamine H2 -receptor 
antagonists (H2RAs) and omeprazole in clinical trials of patients with grade II or III 
(Savary-Miller scale) reflux esophagitis. Studies comparing pantoprazole and H2RAs 
found that pantoprazole had consistently better healing rates and symptom control.  
Abdel-Aziz M. Wahbi., et al., (2002) applied compensation and chemometric 
methods (derivative, orthogonal and difference spectrophotometry) for the estimation 
of omepazole, lansoprazole and pantoprazole in their pharmaceutical preparations. 
The difference spectrophotometry was found to be unaffected by acid induced 
degradation products, thus could be applied for stability indicating assay. 
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Karljikovic–Rajic.K., et al., (2003) developed a first-order UV-derivative 
spectrophotometry in the analysis of omeprazole and pantoprazole sodium salt and 
corresponding impurities. Applied zero-crossing method for the determination of 
omeprazole, omeprazole sulphone, pantoprazole sodium salt, and N-
methylpantoprazole in methanol-ammonia 4.0% v/v. The method showed the 
impurity-drug intermolecular interactions, due to the possible intermolecular 
hydrogen bonds, confirmed by divergences of experimentally obtained amplitudes for 
impurities omeprazole sulphone and N-methylpantoprazole in comparison to 
expected values according to regression equations of calibration graphs. 
Salama F., et al., (2003) validated spectrophotometric determination of omeprazole 
and pantoprazole sodium via their metal chelates. The procedures are based on the 
formation of 2:1 chelates of both drugs with different metal ions. The coloured 
chelates of omeprazole in ethanol are determined spectrophotometrically at 411, 399 
and 523nm using iron (III), chromium (III) and cobalt (II) respectively. 
Incilay Suslu., et al., (2003) developed first derivative spectroscopy for the 
estimation of pantoprazole using 1: 9 ratio of water: methanol as the diluent; λmax of 
295 nm and 303 nm for standard comparison and Zero crossing point respectively.  
Lix Q., et al., (2004) compared the inhibitory effects of the proton pump-inhibiting 
drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on 
human cytochrome P450 activities. It was suggested that, although the inhibitory 
profiles of the five studied PPIs were similar, lansoprazole and pantoprazole are the 
most potent in-vitro inhibitors of CYP2C19 and CYP2C9, respectively. Nafisur 
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Rahman., et al., (2006) devised a kinetic spectrophotometric method based on the 
oxidation of pantoprazole with Fe(III) in sulfuric acid medium. The reaction was 
followed spectrophotometrically by measuring the increase in absorbance with time 
(1 - 8 min) at 725 nm. The initial rate method was adopted for constructing the 
calibration graph, which is linear in the concentration range of 5 - 90 µg mL-1. 
Bardhan K., et al., (D, (2007) performed a clinical trial comparing pantoprazole and 
esomeprazole to explore the concept of achieving 'complete remission' in gastro-
oesophageal reflux disease. Thus, complete   remission is a more reliable and 
clinically relevant endpoint of treatment. 
Akheel Ahmed Syed., et al., (2007) demonstrated a spectrophotometric 
determination of certain proton pump inhibitors using new reagents such as 
neocuproine and bathocuproine. Spectrophotometric methods were developed for the 
determination of antiulcer drugs namely omeprazole, lansoprazole, pantoprazole, 
rabeprazole and esomoprazole. 
Basavaiah K., et al., (2007) determined pantoprazole by colorimetric methods using 
bromate –bromide, methyl orange and indigo carmine as the colouring agents. The 
methyl orange complex showed λmax at 520 nm and indigo carmine complex at 
610nm. 
Syed AA., et al., (2008) developed a spectrophotometric method for the 
determination of certain proton pump inhibitors belonging to the benzimidazole class 
of compounds. The method is based on the reaction of omeprazole, lansoprazole, 
pantoprazole, rabeprazole and esomeprazole with iron (III) and subsequent reaction 
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with ferricyanide under neutral condition which yields Prussian blue product with 
maximum absorption at 720-730 nm.   
Pimpodkar N.V., et al., (2008) developed visible spectrophotometric method by the 
oxidative coupling of pantoprazole by MBTH reagent in the presence of ferric 
ammonium sulphate and observed λ max at 504nm. 
 Urdigere Rangachar.,  et al., (2008) developed visible spectrophotometric method 
by the redox and complexation method using N-bromosuccinimide and iron II 
thiocyanate and tiron reagents. Coupling of pantoprazole by MBTH reagent in the 
presence of ferric ammonium sulphate and measuring the absorbance at a λ max of 
504nm. 
Kanakapura Basavaiah., et al., (2009) developed titrimetric and visible 
spectrophotometric methods for pantoprazole. Both methods involve reaction of 
pantoprazole with excess potassium permanganate in sulphuric acid and indirectly 
determining the amount of pantoprazole by titrating with iron II solution for titrimetry 
and measuring the absorbance at 545 nm for the spectrophotometry. 
 Kakde R.B.,  et al., (2009) developed three-wavelength spectrophotometric method 
for simultaneous estimation of pantoprazole and domperidone in pharmaceutical 
preparations. The method utilizes a wavelength at which domperidone has zero 
absorbance for the determination of pantoprazole. 
Basavaiah. K., et al., (2009) determined pantoprazole by colorimetric methods using 
N-bromo succinimide, methyl orange and indigo carmine as the colouring agents. 
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The methyl orange complex showed λmax at 520 nm and indigo carmine complex at 
610nm. 
 Paluru Rudra Mohan Reddy.,  et al., (2010) developed a stability indicating fast 
LC method for the estimation of impurities of pantoprazole in tablet dosage forms. 
The method utilizes gradient elution technique, mobile phase consisting of 
ammonium acetate buffer – acetonitrile at a flow rate of 0.8mL/min and detected at 
290 nm  
Kalaichelvi R., et al., (2010) developed a extractive colorimetric determination of 
pantoprazole sodium by acid-dye complexation method in solid dosage form using 
bromothymol blue dye for the complexation. The complex showed λmax  at 428nm. 
Basavaiah K., et al., (2010) determined pantoprazole by colormetric methods using 
potassium permanganate as the colouring agent in neutral medium and measured 
absorbance at 350nm. 
Krishna R. Gupta., et al., (2010) developed simultaneous UV spectrophotometric 
method for the estimation of pantoprazole and itopride in capsule dosage form. 
Simultaneous equation method and absorbance ratio method have applied for the 
estimation.  
Prasanna Reddy Battu., et al., (2011) developed and validated   a simple, selective, 
accurate High Performance Liquid Chromatographic (HPLC) method for the 
estimation of pantoprazole sodium sesquihydrate in pharmaceutical dosage forms and 
human plasma.Chromatographic separation was achieved isocratically on a C18 
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column utilizing a mobile phase of acetonitrile/phosphate buffer (70:30, v/v, pH 7.0) 
at a flow rate of 0.8 mL/min and UV detection at 260 nm   
Rajnish Kumar.,  et al., (2011) developed UV spectroscopy for the estimation of 
pantoprazole in pharmaceutical dosage forms using distilled water as the diluent and 
λmax at 292 nm 
Arunadevi S. Birajda.,  et al., (2011) developed simultaneous estimation method  
for pantoprazole and  mosapride  in fixed dose combination by RP- HPLC and UV . 
The methods adopts 274 and 288.2 nm for the simultaneous estimation by UV and 
30 mM ammonium sulphate buffer : acetonitrile (50:50v/v)  as the mobile phase for 
RP- HPLC.  
Kanakapura Basavaiah., et al., (2011) developed titrimetric and visible 
spectrophotometric methods for pantoprazole. Both methods involve reaction of 
pantoprazole with excess ceric ammonium sulphate and indirectly determining the 
amount of pantoprazole by titrating with iron II solution for titrimetry and measuring 
the absorbance at 545 nm for the spectrophotometric method. 
Juana Isabel Balderas., et al., (2011) studied the bioavailability of two coated-
tablet formulations of a single dose of pantoprazole 40 mg comparison in healthy 
mexican adult volunteers. 
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AIM AND OBJECTIVE OF WORK 
Analysis of drugs plays a major role in the development, manufacture and 
therapeutic use of drug. Quantitative analysis of raw materials and the final product 
is necessary to ensure that they meet certain specifications and to ascertain the 
amount of each component in the final product. 
Standard analytical procedures for newly designed and synthesized drugs are 
not available in any of the pharmacopoeias. So it becomes necessary to develop 
newer, accurate, specific, simple, easy to perform, reliable and economic analytical 
techniques for the estimation of the new drugs. 
This thesis deals with pantoprazole (PNP) and cinitapride (CNP). 
Pantoprazole has been recently included in Indian Pharmacopoeia – 2010. 
Cinitapride is a very new drug, launched in 2007 and is not official in any of the 
pharmacopoeias. It has been very recently added in drug bank in 2012.  The 
combination of the two drugs has been launched in 2011.Extensive literature survey 
reveals that only first derivative and HPTLC method for the determination of 
pantoprazole (PNP) and cinitapride (CNP)   has been reported. There is no evidence 
for the estimation of PNP and CNP by UV-Visible spectrophotometry and RP-HPLC 
methods in bulk and in combined tablet dosage form. So, an attempt has been 
made is to develop a validated, simple, easy to perform, accurate, cost effective 
and rapid spectrophotometric methods for the estimation of CNP and PNP in 
bulk and combined oral dosage form.  
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PLAN OF WORK 
1. Procurement of Gift samples of PNP and CNP. 
2. Development of simple and accurate UV – Visible spectrophotometric methods.  
 Standard absorbance method            
 Area under curve         
  Second derivative spectroscopy 
 Visible spectrophotometry 
 Colorimetry (Diazotisation followed by coupling for CNP) 
 Colorimetry (Redox method for PNP) 
3.  Development of rapid and accurate RP-HPLC method using UV detection 
4. Validation of proposed analytical methods. 
5.   Statistical analysis of developed analytical methods 
6.  Comparison of obtained results for the developed methods    
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MATERIALS AND METHODS 
MATERIALS 
DRUG SAMPLES 
Cinitapride pure drug sample  was generously gifted by  M/S Zydus Cadila, 
Ankleshwar, Gujarat (India) and Pantoprazole by M/S Knis Laboratories, Chennai, 
TN (India).The combined capsule dosage form was acquired from the local market. 
The capsule contained within it enteric coated tablet of pantoprazole sodium 
sesquihydrate equivalent to 40 mg of PNP and extended release tablet of cinitapride 
hydrogen tartarate equivalent to 3 mg of cinitapride. 
REAGENTS AND CHEMICALS 
All the chemical used in the study were of analytical grade and procured from 
Merck India ltd.The chemicals used during the study are 
S.no Chemicals Grade 
1. Methanol Analytical grade 
2. Water Double distilled water,  
HPLC grade for HPLC 
3. Methanol HPLC grade for HPLC 
4. Acetonitrile HPLC grade for HPLC 
5. Potassium dihydrogen orthophosphate Analytical grade 
Department of Pharmaceutical Chemistry Page 37 
 
6. Potassium bromate Analytical grade 
7. Potassium bromide Analytical grade 
8. FAS Analytical grade 
9. Ammonium Thiocyanate Analytical grade 
10. 1,10 phenanthroline Analytical grade 
11. EAA, AAC Analytical grade 
 
INSTRUMENTS  
1. Digital Balance 
2. Shimadzu UV-Visible spectrophotometer, Model 1650PC  
3.   A Shimadzu Prominence LC-20AT with SPD-20A UV detector -HPLC 
4.   pH meter 
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ULTRA VIOLET- VISIBLE SPECTROSCOPY 
General discussion 
Ultraviolet spectroscopy is most frequently employed technique in 
pharmaceutical analysis. The ultraviolet region of the electromagnetic spectrum is 
used in the analysis which extends from 200-400 nm. It involves transitition of 
electrons of  pi orbitals and lone pairs   (n = non bonding) so UV spectroscopy is of 
most use for identifying conjugated systems. 
            Choice of solvent (Sharma, 1994; Chatwal and  Anand, 2000) 
            The most important requirement of the solvent are: 
• It should solubilize the analyte freely. 
• It should not itself absorb in the region of the analyte. 
• It should not undergo association or dissociation with the analyte 
The Absorption laws (Sharma YR, 2010) 
       There are two laws which govern the absorption of light by the molecules. 
Theyare, 
o Lambert-Bouger’s law 
o Beer’s law 
Lambert-Bouger’s law 
    It states that, when a beam of monochromatic radiation passes through a 
homogenous absorbing medium the ratio of decrease of intensity of transmitted 
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radiation with thickness of absorbing medium is directly proportional to the intensity 
of the incident radiation.  
  The law is given by:                      I=I010 - ax 
 Where, I0 is the intensity incident light;  I is the intensity of transmitted light. 
Beer’s law 
            This law states that, when a beam of monochromatic radiation is passed 
through a solution of an absorbing substance, the rate of decrease of intensity of 
transmitted radiation with concentration of the absorbing solution is directly 
proportional to the intensity of incident radiation.  The law is given by: 
I=I0 e-k’cx 
On combining these two laws ,the Beer- Lambert law is formulated 
Log I0/I = a .c.l = A 
Where, I0 =  intensity incident light;   I  =  intensity  of transmitted light 
 a = Molar extinction coefficient;   c  =  concentration of solute in moles litre-1 
  l  =  pathlength of the sample ( usually 1 cm);    A = absorbance 
Quantitative analysis  
The use of UV in quantitative analysis employs the method of comparing the 
absorbances of the standard and samples at selected wavelength. (Metreyi, 2008) 
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Assay of Substances in single Component Samples (Beckett and Stenlake, 2002) 
The most important characteristics of photometric and spectrophotometric 
methods are high selectivity and ease of convenience. Quantitative analysis (assay of 
an absorbing substance) can be done using following methods. 
• Use of A (1%, 1cm) values 
 This method can be used for the estimation of formulation or raw material 
when reference standard not available. The use of standard A (1%, 1cm) value 
avoids the need to prepare a standard solution of the reference substance in order to 
determine its absorption. 
• Use of calibration graph 
 In this method a calibration curve is plotted using concentration (X-axis) Vs 
absorbance (Y-axis) with the value of five  or more standard solutions. A straight 
line is drawn through maximum number of points. This line is called line of best fit. 
By interpolating the absorbance of the sample solution on the calibration chart, the 
concentration of the drug amount and percentage purity can be calculated. This is 
used in the new method development for the estimation of an analyte by UV- Visible 
spectrophotometry. 
The amount present can be calculated using the formula 
Amount present
Sample absorbance
Standard absorbance
(Dilution factor(
Wt of Std
Wt of Sample
(Avg /0 
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• For Area under Curve, instead of absorbance , Area is used. 
• For Derivative spectrophotometry, Amplitude of negative maxima is used 
instead of absorbance. 
VISIBLE SPECTROPHOTOMETRY 
  The visible spectrophotometry follows the same Beer- Lamberts law. But the 
abasorbance of the analyte is observed in the Visible region (380 nm to 
800nm).Analytes which do not have absorbing chromophore in their structure are 
chemically derivatized by chromogenic reactions to form a coloured complex which 
show bathochromic shift towards the visible region. There different complexing 
methods and corresponding complexing agent. 
1. Diazotisation followed by coupling reaction to form diazo dyes 
2. Complexes involving redox reactions and reagents. 
3. Acid dye techniques involving ion pair reagents like Bromothymol 
blue,Bromocresol green, Eriochrome black II. Methyl red etc 
4. Reagents specific for phenols- 2,6 dichloro indo phenol 
5. Reagents specific for primary amines- PDAB (para dimethyl amino 
benzaldehyde, MBTH (3-methyl 1,2 benzothiazoline hydrazone hydrochloride) 
etc. 
 While developing methods for estimation of analytes using UV –Visible 
spectrophotometry following criterias are considered 
• Adherence to Beer’s law. 
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• Stability of the drug in the solvent /diluents. 
• Selectivity of the complexing agent in colorimetry. 
• Stability of the complex, colour of the complex. 
• Stability of absorbance with respect to time ,pH, temperature, ionic strength  
etc.  
METHODS 
I. ULTRA VIOLET SPECTROPHOTOMETRIC METHOD 
SELECTION OF SOLVENT ( IP,2010) 
The solubility of CNP and PNP were studied as per Indian Pharmacopoeial 
standards. The solubility of the drugs was tested in both polar and non polar solvents. 
Both the drugs were found to be freely soluble in methanol. So methanol was 
selected for further studies on CNP and PNP by UV spectroscopy. 
PREPARATION OF STANDARD STOCK SOLUTION 
Weighed accurately about 50 mg each of standard CNP and PNP in two separate 
50mL volumetric flasks. Dissolved in 10 mL of methanol and made up to volume 
with methanol to obtain stock solutions of concentration 1000 µg/mL of both CNP 
and PNP.  
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SELECTION OF ABSORPTION MAXIMA  
 The stock solutions of both CNP and PNP were appropriately diluted to obtain a 
concentration of 10 µg/ mL. The dilutions were scanned in ultra violet region (200-
400nm) against methanol blank. CNP showed maximum absorbance at 262nm and 
PNP at 290 nm. Thus λ max for CNP and PNP were selected as 262 and 290 nm 
respectively and used during further studies for the estimation of CNP and PNP by 
UV spectrophotometry. 
ESTABLISHMENT OF LINEARITY 
CINITAPRIDE 
The stock solution (1000 µg/ mL) of CNP was serially diluted with methanol 
to obtain dilutions ranging 4-20 µg/ mL.  The final dilutions were scanned in 
ultraviolet region (200-400nm) against methanol blank. The λ max was found to be 
stable at 262nm. The absorbance of the dilutions was measured at the selected λ max, 
262nm.  
PANTOPRAZOLE 
The stock solution (1000 µg/ mL) of PNP was serially diluted with methanol 
to obtain dilutions ranging 5-30 µg/ mL.  The final dilutions were scanned in 
ultraviolet region (200-400nm) against methanol blank. The λ max was found to be 
stable at 290 nm. The absorbance of the dilutions was measured at the selected λ 
max, 290 nm. 
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SAMPLE ANALYSIS 
The capsule dosage form contained PNP as enteric coated tablet and CNP as 
extended release tablet. Thus both the components were analyzed as separate entities 
METHOD A: STANDARD ABSORBANCE METHOD 
CINITAPRIDE 
Twenty tablets of CNP were accurately weighed and crushed to fine powder. 
Tablet powder equivalent to 10mg of the CNP was weighed in a 100 mL  
volumetric flask, shaken vigorously with sufficient quantity of methanol for half an 
hour. Finally the solution was made up to volume with methanol. The solution was 
well shaken and filtered through Whatmann filter paper (No.41). First few mL of the 
filtrate was discarded and an aliquot quantity of the filtrate was diluted to obtain a 
final concentration of 10µg/mL of CNP. The absorbance of the resulting solution 
was measured at 262nm against methanol blank. 
 PANTOPRAZOLE 
Twenty tablets of PNP was accurately weighed and crushed to fine powder. 
Tablet powder equivalent to 50mg of PNP was weighed in a 100mL volumetric 
flask, shaken vigorously with sufficient amount of methanol for half an hour and 
finally made up to volume with methanol. The resulting solution was filtered through 
Whatmann filter paper (No.41). First few mL of the filtrate was discarded and 
sufficient quantity of the filtrate was diluted with methanol to obtain a final 
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concentration of 15µg/mL of PNP. The absorbance of the resulting solution was 
measured at 290 nm against methanol blank. 
METHOD B: AREA UNDER CURVE  
The AUC (area under curve) method involves the calculation of integrated 
value of absorbance between two selected wavelengths λ1 and λ2. The wavelength 
range is selected on the basis of repeated observations so as to get the linearity 
between area under curve and concentration. The standard spectra obtained in the 
linearity characterization and the sample spectra for both CNP and PNP obtained in 
method A were used. The AUC for CNP were determined between 239.8 and 296.4 
for both standard and sample.  
Similarly for PNP, the AUC between 248.4 and 314.0 nm nm for both 
standard and sample were determined. The calibration graph was plotted between 
AUC and concentration. The sample AUC was interpolated on the respective 
linearity chart and the concentration was determined.  
METHOD C: SECOND DERIVATIVE 
            The zero order spectra obtained in the linearity characterization and method 
A for both CNP and PNP were derivatized to get second order spectra. CNP showed 
a negative maxima at 262nm and PNP at 290nm. The amplitude of the negative 
maxima were measured and plotted against concentration to determine the linearity. 
The sample amplitudes were interpolated on the respective linearity chart of the 
derivative spectra and the concentration was determined.  
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RECOVERY STUDIES 
 The recovery studies were carried out on spiked samples by adding 
predetermined amount of standard drugs to the respective preanalysed sample. About 
20, 40 and 100% of standard drugs were added to the sample solutions and the 
absorbance was measured against methanol blank. The percentage recovered was 
calculated. The recovery studies were performed at three levels for all the three 
methods to confirm the accuracy of the above said methods. 
II. VISIBLE SPECTROPHOTOMETRIC METHOD 
Two different colorimetric methods were developed for the estimation of 
both Cinitapride and Pantoprazole each. 
CINITAPRIDE 
The developed visible spectrophotometry of CNP is based on the 
diazotization followed by coupling reaction. Method A involves the coupling of 
diazotized CNP with ethyl aceto acetate (EAA). Method B involves the coupling of 
diazotized CNP with acetyl acetone (AAC).  
PREPARATION OF REAGENTS 
• Sodium nitrite solution (2%):  
     2gms of sodium nitrite dissolved in water and made up to 100 mL with    distilled 
water. 
• Hydrochloric acid 0.5M:   
     42.5 mL of concentrated hydrochloric acid was made up to 1000 mL with 
distilled water. 
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• Ethyl aceto acetate (EAA) (2%) solution:  
    2 mL of acetyl acetone was dissolved in 5mL of alcohol and made up to       
volume with water in a 100 mL volumetric flask. 
• Acetyl acetone(AAC) (2%) solution: 
    2 mL of acetyl acetone was dissolved in 5mL of alcohol and made up to volume 
with water in a 100 mL volumetric flask. 
• Sodium hydroxide 1 mol L-1:  
     4gms of sodium hydroxide was dissolved and made up to 100 ml with distilled   
water. 
METHOD A — USING ETHYL ACETO ACETATE (EAA) 
SPECTRAL CHARACTERIZATION AND ESTABLISHMENT OF LINEARITY 
           A stock solution of CNP was prepared by dissolving accurately weighed 
quantity of standard CNP in 10 m l of methanol and made up to volume with water 
to obtain a concentration of 500 µg/ml. From the stock solution 1.0, 2.0, 3.0, 4.0, 5.0 
and 6.0 mL were transferred into six 50 mL volumetric flasks. The solutions were 
diazotized by the addition of 2 mL of 2% sodium nitrite solution and 2 mL of 0.5 M 
hydrochloric acid at a temperature of about 0-5° C for 5 minutes. Then 2 mL of 2 % 
EAA was added to each reaction mixture followed by the addition of 1 mL of 1M 
sodium hydroxide, when a reddish orange coloured chromogen was formed. Finally 
the solutions were made up to volume with distilled water and shaken well. The 
absorbance of the reddish orange coloured chromogen was scanned between 350-
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800nm against distilled water blank. The chromogen gave maximum absorbance at 
392.5 nm. 
ANALYSIS OF FORMULATION 
           Twenty tablets of CNP from the capsules were accurately weighed and 
ground to fine powder. Tablet powder equivalent to 25 mg of CNP was accurately 
weighed and dissolved in 10 mL of methanol, made up to volume with water to 
obtain a concentration of 250 µg/mL. The solution was filtered through Whatmann 
filter paper No.41. First few mL of the filtrate was discarded, and then 6 mL of the 
filtrate was transferred to a 50 mL volumetric flask. The sample solution was 
diazotized, coupled with EAA using the same procedure as that of standard CNP. 
The absorbance of the resulting chromogen was measured at 392.5 nm.  
METHOD B — USING ACETYL ACETONE (AAC) 
SPECTRAL CHARACTERIZATION AND ESTABLISHMENT OF LINEARITY 
A stock solution of CNP was prepared by dissolving accurately weighed 
quantity of standard CNP in sufficient amount of methanol  and made up to volume 
with  distilled water to obtain a concentration of 1000 µg/mL. From the stock 
solution 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mL were transferred into six 50 mL volumetric 
flasks. The solutions were diazotized by the addition of 2 mL of 2% sodium nitrite 
solution and 2 mL of 1M hydrochloric acid at a temperature of about 0-5° C for 5 
minutes. Then 2 mL of 2 % AAC was added to each reaction mixture followed by 
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the addition of 1M sodium hydroxide, when a reddish orange coloured chromogen 
was formed. Finally the solutions were made up to volume with distilled water and 
shaken well. The absorbance of the reddish orange coloured chromogen was scanned 
between 350-800nm against distilled water blank. The chromogen gave maximum 
absorbance at 399nm. 
ANALYSIS OF FORMULATION  
Twenty tablets of CNP from the capsules were accurately weighed and 
ground to fine powder. Tablet powder equivalent to 25 mg of CNP was accuratey 
weighed and dissolved in methanol and shaken well for  20 minutes, made up to 
volume with water to obtain a concentration of 250µg/mL. The solution was filtered 
through Whatmann filter paper No.41. First few mL of the filtrate was discarded, and 
then  6 mL of the filtrate was transferred to a 50 mL volumetric flask. The sample 
solution was diazotized, complexed with AAC similar to that of standard CNP and 
the absorbance of the resulting solution was measured at 399nm. 
PANTOPRAZOLE  
 The visible spectrophotometric studies of PNP is based on the oxidation of 
PNP by excess of bromine and  indirectly determining the amount of PNP using 
ferrous ammonium sulphate and 1,10 phenanthroline in Method A and ammonium 
thiocyanate in Method B. 
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PREPARATION OF REAGENTS 
• Potassium bromate – bromide mixture : 
Dissolved 100 mg of potassium bromate and 1g of potassium bromide in 10 mL 
of water and made up to volume in a 100 mL volumetric flask. Appropriate 
dilution of the stock solution was made to obtain a concentration of and 35 
µg/mL and 20 µg/mL to be used in method A and B respectively.  
• Ferrous ammonium sulphate: 
Dissolved 400 mg of FAS in 50 mL of distilled water, added 1 mL of dilute 
sulphuric acid and made up to 100 mL in a volumetric flask. Further dilutions 
were made to obtain a concentration of 350 µg/mL and 400 µg/mL of FAS to be 
used in method A and B respectively. 
• 1,10 – Phenanthroline: 
Dissolved 250 mg of 1, 10 – Phenanthroline in distilled water with the aid of heat 
and made up to volume in 100 mL volumetric flask. 
• Hydrochloric acid (5M-): 
About 43 mL of concentrated hydrochloric acid in water was added in to 10mL 
of distilled water, made up to volume in 100 mL volumetric flask with distilled 
water. 
• Hydrochloric acid (1M) 
About 85 mL of concentrated hydrochloric acid was added in to 100 mL of 
distilled water, made up to volume in 1000 mL volumetric flask with distilled 
water. 
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• Ammonia solution (50 %) 
About 50 mL of strong ammonia solution was added to 20 mL distilled water and 
made up to 100 mL with distilled water 
• Ammonium thiocyanate (3 mol L-1) 
Dissolved 23g of ammonium thiocyanate in water and made up to 100 mL with 
distilled water. 
• Hydrochloric acid (5 mol L-1-) 
 About 15.4 mL of concentrated hydrochloric acid was added into100 mL water 
and made up to volume in 1000mL volumetric flask with distilled water. 
PREPARATION OF STANDARD STOCK SOLUTION  
            A stock solution of PNP was prepared by dissolving accurately weighed 
quantity of standard PNP in 1M hydrochloric acid and made up to volume with the 
same hydrochloric acid to obtain a final stock concentration of 1000 µg/mL.  
METHOD A— USING 1, 10 – PHENANTHROLINE 
SPECTRAL CHARACTERIZATION AND ESTABLISHMENT OF LINEARITY 
            The stock solution was further diluted with distilled water to obtain a 
working standard solution of concentration 30 µg/mL. Transferred 1 – 4.5 mL of the 
working standard solution of PNP (30µg/mL) into six 25 mL volumetric flasks. To 
each flask was added 2 mL of potassium bromate – bromide mixture (35µg/mL) 
using a burette and 2 mL of hydrochloric acid (5M), stoppered immediately, shaken 
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well and kept aside for 5 minutes. To the reaction mixtures,  about 2 mL of FAS was 
added (350 µg/mL), shaken well and again kept aside for fifteen minutes until the 
reaction is completed.  This  was  followed  by  the  addition  of 2 mL of 1, 10- 
phenanthroline, when a blood red coloured chromogen is obtained. Finally the 
solutions were made up to volume with distilled water. The absorbance of the 
reddish coloured chromogen was scanned between 350-800nm against reagent blank. 
The chromogen gave maximum absorbance at 510 nm.  
ANALYSIS OF FORMULATION 
             Twenty tablets of PNP from the capsules were accurately weighed and 
ground to fine powder. Tablet powder equivalent to 50mg of CNP was accurately 
weighed and shaken well with 1M hydrochloric acid for 20 minutes and made up to 
volume with 1M hydrochloric acid to obtain a concentration of 1000µg/mL. The 
solution was filtered through Whatmann filter paper No.41. First  few mL of the 
filtrate was discarded and the filtrate was appropriately diluted to obtain a 
concentration of 30 µg/mL with water. Transferred 3 mL of the first dilution 
(30µg/mL) to a 25mL volumetric flask and the same procedure for standard PNP 
was followed. The absorbance of the resulting solution was measured at 510nm. 
METHOD B—USING AMMONIUM THIOCYANATE 
SPECTRAL CHARACTERIZATION AND LINEARITY ESTABLISHMENT 
             A stock solution of PNP was prepared by dissolving accurately weighed 
quantity of standard PNP in 1M hydrochloric acid and made up to volume with the 
same hydrochloric acid to obtain a final stock concentration of 1000µg/mL. The 
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stock solution was further diluted with distilled water to obtain a working standard 
solution of concentration 20 µg/mL. Transferred 0.5, 1, 1.5, 2, 2.5 and 3 mL of the 
working standard solution of PNP (20µg/mL) into six 25 mL volumetric flask. To 
each was added 2 mL of potassium bromate – bromide mixture (40µg/mL) using a 
burette and 2mL of hydrochloric acid (5M), stoppered immediately, shaken well and 
kept aside for 5 minutes. To the reaction mixtures, about 2 mL of FAS (400µg/mL) 
was added, shaken well and again kept aside for fifteen minutes until the reaction is 
completed.  This was followed by the addition of 1mL of 3 mol L-1 ammonium 
thiocyanate when a blood red coloured chromogen is obtained. Finally the solutions 
were made up to volume with distilled water. The absorbance of the reddish coloured 
chromogen was scanned between 350-800nm against reagent blank. The chromogen 
gave maximum absorbance at 477 nm. 
ANALYSIS OF FORMULATION 
            Twenty tablets of PNP from the capsules were accurately weighed and 
ground to fine powder. Tablet powder equivalent to 50 mg of PNP was accurately 
weighed and shaken well with 1M hydrochloric acid for 20 minutes and made up to 
volume with 1M hydrochloric acid to obtain a concentration of 1000µg/mL. The 
solution was filtered through Whatmann filter paper No.41. First few mL of the 
filtrate was discarded and the filtrate was appropriately diluted to obtain a 
concentration of 20µg/mL with distilled water. Transferred 1mL of the first dilution 
(20µg/mL) to a 25mL volumetric flask and the same procedure for standard PNP 
was followed. The absorbance of the resulting solution was measured at 477 nm. 
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
  The ability to separate and analyse complex samples is integral to the 
biological and medical sciences. The innovations and development in the classic 
column chromatography chromatographic techniqueshas offered major 
improvements in speed, resolving power, detection, quantification, convenience and 
applicability to new samples types. 
 Modern HPLC techniques  became available in 1969, but not widely used in 
pharamaceuticals. Once HPLC systems capable of quantitative analysis became 
commercially available, their application in pharma industry became exclusive. 
GENERAL PRINCIPLE OF CHROMATOGRAPHY 
Generally chromatographic separation technique makes use of any of the  
four mechanism: 
• Adsorption : Separation arises due to difference in affinity of                    
compounds towards solid stationary phase generally makes use of Normal 
phase  
• Partition: Separation arises due to difference in affinity of compounds 
towards liquid stationary phase that is immiscible with the eluent and coated 
on an inert support. Could be normal or reverse phase 
• Ion exchange involves solid stationary phase called Ion exchange resin is 
used  to separate mixture of similar charged ions. 
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• Ion pair: An alternative to ion exchange chromatography Reverse phase 
column is used to separate ionic compounds. It involves the addition of an 
organic ionic substance to the mobile which forms an ion pair with sample 
component of opposite charge. 
• Size exclusion: A mixture of components with different molecular sizes are       
separated by using gels as the stationary phase with controlled pore size 
• Chiral phase: Separation of enatiomers  by using either chiral stationary 
phases or the chiral mobile phase   
Modes of chromatography (Mendham, et al. 2002) 
Normal phase chromatography, the stationary phase is more polar than the mobile 
phase which is a mixture of organic solvents without added water (eg : Isopropane  
with hexane ) and the column packing is either an inorganic adsorbent (silica) or a 
polar bonded phase (cyano, diol, amino) on a silica support. Sample retention in 
normal phase chromatographic technique increases as the polarity of the mobile 
phase decreases.  
Reverse phase chromatography is the chromatography in which the stationary 
phase is less polar than the mobile phase and the mobile phase is a mixture of 
organic and aqueous phase. Reverse phase chromatography is more convenient and 
rugged than the other form of liquid chromatography and is more likely to result in a 
satisfactory final separation. RP –HPLC columns are efficient, stable and 
reproducible.  
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Choice of column chromatography system  
 To select the most appropriate column type, understand the physical 
characteristics of the sample and the type of information required. The following 
chart shows a guard guide to selecting chromatographic methods for separating 
compound based on their relative molecular species. 
               
 
 
 
 
 
 IC- Ion exchange chromatography;  LSC – Liquid solid chromatography  
BPC – Bonded phase chromatography;  RPC – Reverse phase chromatography 
Choice and optimization of the mobile phase (James W. Munson 2001) 
 The power of HPLC in term of being able to resolve many compound is 
mainly due to the diversity of mobile phase (or) mobile solvent available. The 
mobile phase in HPLC however has a great influence on the retention of the solutes 
and the separation of component mixtures. The viscosities, compressibility, 
refractive index, UV cut off, Polarity, vapour pressure of the solvent are considered 
while  selecting  a mobile phase.   The best mobile phase  and its strength for a 
specific separation can be determined primarily by performing asilica  TLC. The 
results are readily transferable to HPLC and k' (capacity factory) values can be 
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predicted if the stationary phase in both methods is the same product but with a 
different in particle size. 
Separation/Elution technique: There are two types of elution technique 
Isocratic elution technique: When the mobile phase compositions do not change 
throughout the course of run, it is said to be isocratic. This is the simplest technique 
and should be the method of first choice when developing a separation 
Gradient elution technique: When the mobile phase composition is changed over 
time during  the course of run, it is said to be gradient elution technique. The elution 
strength of the eluent is increased during the gradient run by changing the polarity, 
pH, or ionic strength. This technique is a powerful tool to separate mixtures of 
compounds with different retention. 
Derivatisation:  
Derivatisation involves chemical reaction that alters the molecular structure 
of the analyte of interest to improve detection. It is used to enhance the sensitivity 
and selectivity of detection when the available detectors are not satisfactory for the 
underivatised compounds.  A good derivative should be stable, low background, 
convenience etc. Both UV and Fluorescent derivatives are used. Some of the 
derivatizing agents are:  N-succinimidyl-p-nitrophenylacetate (SNPA), phenyl 
hydrazine, 3,5-dinitrobenzoyl chloride (DNBC), dansyl chloride (DNS-Cl), 4-
bromomethyl-7-methoxy coumarin (BMC) and flourescamine (FC). 
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Quantitative Analysis 
Quantification by HPLC basically involves measurement of peak height(or) peak 
area. Well resolved peak’s peak area and peak height are proportional to the 
concentration. Similar to UV quantification, Beer’s concentration is established for 
the standard analytes and calibration curve is plotted by taking peak height(or) peak 
area along X-axis and concentration along  Y-axis.  The plot should be a linear line 
essentially passing through the origin. There are three different quantification 
techniques. 
1. External standard method: 
This is the simplest and accurate method. Linearity is established for the 
standard drug (peak area vs. concentration) and beer’s concentration is determined. 
A concentration of the test sample essentially lying in the Beer’s range is also 
studied and interpolated on the calibration chart to attain the sample concentration. 
Concentration  can be calculated using the following formula:      
 
1234 56332738 
9:;< 56332738  
9:;<532738  
( 1234 532738 
    
2. Internal standard method 
This method tends to yield the most accurate and precise results. In this 
method an equal amount of internal standard that is not present in sample is added to 
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both the sample and standard solutions. Quantification is achieved using the ratios of 
peak height (or) peak area of the component to the internal standard  
3. Standard addition method 
This is especially useful to determine the or identify problems due to 
interference from sample matrix, since it cancels out these effects. In this method the 
sample is divided in to two portions. To one portion a known amount of the analyte 
(spike) is added. The original and the original plus spike is analysed. The sample 
with spike shows a larger response than the original sample due to the additional 
amount of analyte.  
Applications of HPLC in the pharma industry 
Present applications of HPLC in pharmaceutical research and development are: 
 To purify synthetic or natural products 
 To characterize metabolites and in pharmacodynamic and kinetic studies. 
 To assay APIs, impurities, degradation products and in dissolution assays 
Hyphenated techniques/Hybrid Techniques 
These have improved the ability to separate and identify multiple entities within a 
mixture. The techniques include HPLC – MS, HPLC – MS / MS, HPLC – IR, and 
HPLC – NMR. These techniques involve usual chromatography separation followed 
by peak identification using traditional detector such as UV, combined with further 
identification of the   compound with MS, IR, NMR, and DAD.  
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III. REVERSE PHASE - HIGH PERFORMANCE LIQUID 
INSTRUMENT 
High Performance Liquid Chromatograph 
1. Shimadzu prominence 
2. UV-Visible Detector (SPD 20A) 
3. Auto sampler 
4. Isocratic (LC-20AT) pump 
5. Rheodyne Valve injector with 20 µl fixed loop 
6. Chromatographic Column- Phenomenex Gemini, C18(5 µ) :  250x4.60 mm i.d  
PREPARATION OF MOBILE PHASE 
The mobile phase consisted of acetonitrile, methanol and phosphate buffer 
(pH-7) in the ratio of 40:20:40. Phosphate buffer was made from 0.2M potassium 
dihydrogen orthophosphate adjusted to pH-7 with triethylamine. The mobile phase 
was filtered through 0.2µ membrane filter and used throughout the study. 
SELECTION OF WAVE LENGTH (IP, 2010) 
A known concentration of standard CNP was prepared in methanol The 
solution was further appropriately diluted with the mobile phase containing 
acetonitrile, methanol and phosphate buffer (pH-7) in the ratio of 40:20:40%v/v to 
obtain a concentration of 10 µg/ml. The solution was then scanned in the UV region 
Department of Pharmaceutical Chemistry Page 61 
 
in the UV spectrophotometer against the mobile phase as the blank. The λmax was 
observed at 262nm.  The     λmax was     analysed using different ratios of mobile 
phase, different pH of the buffer. There was no significant change in the λmax. So 262 
nm was selected as the detection wavelength for the estimation CNP by RP-HPLC.    
                    Similarly 10 µg/ml concentrated solution of PNP was prepared in 
mobile phase containing acetonitrile, methanol and phosphate buffer (pH-7) in the 
ratio of 40:20:40 to obtain a concentration of 10 µg/ml. The solution was then 
scanned in the UV region in the UV spectrophotometer against the mobile phase as 
the blank. The λmax was observed to be 290nm.  The     λmax was     analysed using 
different ratios of mobile phase, different pH of the buffer. There was no significant 
change in the λmax. So 290 nm was selected as the detection wavelength for the 
estimation PNP by RP-HPLC.    
OPTIMIZATION OF THE MOBILE PHASE 
             Effect of different ratios of mobile phase    
Both the drugs were studied by the RP-HPLC method using different ratios 
of mobile phase like 50:20:30%v/v, 20: 20: 60%v/v and 40:20:40%v/v of acetonitrile 
: methanol :phosphate buffer PH-7.  The shape and symmetry of the peak, the 
retention times were good and acceptable in 40:20:40%v/v mobile phase. So mobile 
phase containing acetonitrile : methanol :phosphate buffer pH-7 in the ratio of 
40:20:40%v/v  was selected for the study of the drugs by HPLC. 
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Effect of pH of mobile phase  
            The different pH solutions were tried i.e. 6.5, 7.0, 7.5, and the 
chromatograms were recorded. On comparing the chromatogram obtained for the 
different pH solutions, at pH 7, the peak was very sharp for both CNP and PNP.  
Effect of flow rate on separation  
 Using the above selected mobile phase (40:20:40%v/v of acetonitrile:  
methanol: phosphate buffer pH-7, separation of both CNP and PNP were tried in 
different flow rates i.e. 1.5 ml/min,  2.0ml/min, 2.5 ml/min. The chromatograms 
were recorded. At 2.0ml/min, the peak was very sharp and the retention time was 
stable at 6.5 minutes and 3.5 minutes for CNP and PNP respectively. 
 OPTIMIZED CHROMATOGRAPHIC CONDITIONS  
The following parameters were used for RP-HPLC analysis of CNP and PNP 
Mode of operation  :   Isocratic 
Stationary phase  :   C18 Column (250 mm × 4.6 mm i.d., 5 µ) 
Mobile phase            :    Acetonitrile, Methanol and Phosphate buffer (pH-7)  
Ratio               :     40:20:40 %v/v 
Detection wavelength :     262 nm (CNP) and 290 nm (PNP) 
Flow rate   :     2.0ml/min 
Temperature        :    Ambient 
Sample volume :    20 µl   
Quantification method:  External Standard Calibration Method 
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Determination of CNP and PNP in bulk and oral dosage form 
Since the combined capsule dosage form contains CNP and PNP as separate 
tablets, they were studied as separate entities. 
CINITAPRIDE 
Preparation of standard solutions and Establishment of Linearity 
Accurately weighed  30mg of standard CNP  in 25 ml volumetric flask, 
dissolved in methanol and made up to volume in methanol to get a concentration of 
0.6 mg/ml of cinitapride. The solution was filtered through 0.2µ membrane filter and 
used. Aliquot quantity of the standard solution (0.6 mg/ml) of CNP was serially 
diluted with the mobile phase to get a concentration range of 84µg/ml to132µg/ml. 
About 20µl of the dilutions were injected one by one in the 20µl loop. The eluate 
was detected at 262nm and the chromatogram was recorded. The peak area was 
plotted against concentration and the linearity was studied using regression analysis. 
Analysis of formulation: 
Twenty tablets of CNP from the formulation were weighed accurately. Tablet 
powder equivalent to 6mg of CNP was then accurately weighed, dissolved in 
methanol with the aid of ultrasonication for 15minutes and made up to volume 
(10ml) with the methanol. The solution was further diluted with mobile phase to 
obtain a concentration of 0.12 mg /ml.The solution was then filtered through 0.2µ 
membrane filter and injected into the column. The eluate was detected at 262nm and 
the chromatogram was recorded. 
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Recovery studies 
To 5ml of preanalysed sample stock solution (0.6mg/ml) 2.5 ml of standard 
stock solution (0.6mg/ml) was added and made up to 25 ml in a volumetric flask.The 
solution was then filtered and  injected in to the column. The eluate was detected at 
262nm and the chromatogram was recorded. 
PANTOPRAZOLE 
Preparation of standard solutions and Establishment of Linearity 
Accurately weighed 100mg of standard PNP in 50 ml volumetric flask, 
dissolved in mobile phase and made up to volume with the mobile phase to get a 
concentration of 2mg/ml of PNP. The solution was filtered through 0.2µ membrane 
filter and used further. Aliquot quantity of the standard solution (2mg/ml) of PNP 
was serially diluted with the mobile phase to get a concentration range of 140µg/ml 
to 220µg/ml. The dilutions were injected in the 20µl loop one by one; the eluate were 
then detected at 290nm and the chromatograms were recorded. The peak area was 
plotted against concentration and the linearity was assessed using regression 
analysis. 
Analysis of formulation:  
Twenty tablets of PNP from the formulation were weighed accurately. Tablet 
powder equivalent to 100mg of PNP was accurately weighed, transferred to 50 ml 
volumetric flask. Dissolved in mobile phase with the aid of ultrasonication for 
15minutes and made up to volume with mobile phase to obtain a concentration of 
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2mg/ml. The solution was further diluted to obtain a concentration of 0.2mg/ml. The 
final dilution was then filtered through 0.2µ membrane filter and 20 µl was injected 
into the column. The eluate was detected at 290nm and the chromatogram was 
recorded. 
Recovery studies 
To 5ml of preanalysed sample stock solution (2mg/ml) 2.5 ml of standard 
stock solution (2mg/ml) was added and made up to 50 ml in a volumetric flask.The 
solution was then filtered and  injected in to the column. The eluate was detected at 
290nm and the chromatogram was recorded. 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION  
 Calibration of standard (CNP and PNP) was repeated for three times.  The 
limit of detection and limit of quantification was calculated by using the average 
value of slope and standard deviation of intercept.  
SYSTEM SUITABILITY STUDIES 
The system suitability studies carried out as specified in ICH guidelines and 
USP.  The parameters like tailing factor, asymmetry factor, number of theoretical 
plate, capacity factor were calculated. 
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RESULTS AND DISCUSSION 
I. ULTRA VIOLET SPECTROSCOPIC METHOD 
METHOD A- STANDARD COMPARISON METHOD 
 CNP was found to be freely soluble in methanol. It gave maximum absorption 
in methanol at 262 nm.(fig-1)  
            
Fig 1: UV spectrum of CNP showing λmax at 262 nm 
   The standard drug was subjected to linearity studies from 2 to 100 µg/mL A 
five point calibration chart was plotted using absorbance along Y–axis and 
concentration along X–axis. It was observed that CNP obeyed Beer’s law at 4–20 
µg/mL. The overlain spectrum of the linearity studies are shown in fig-2.  The 
absorbance with respect to concentration is presented table-1. Above 20µg/mL it 
showed negative deviation from Beer’s law.  
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                 Table 1: Absorbance of CNP at 262 nm  
                               
S.No. 
Concentration 
(µg/mL) 
Absorbance* 
1 4 0.224 
2 8 0.449 
3 10 0.561 
4 12 0.672 
5 16 0.896 
6 20 1.121 
                      *Each value is the mean of three determination 
 
 
                            Fig 2: Overlain spectrum of CNP  
Department of Pharmaceutical Chemistry Page 68 
 
The linearity was assessed by the regression analysis which is shown in fig-3. The 
correlation coefficient was found to be 1 which was within the limit. The formulation 
was quantified.  
 
                    Fig 3: Calibration chart of CNP 
                        Similarly, PNP was also found to be very freely soluble in methanol. 
PNP showed absorption maxima at 290 nm. (fig-4)  
 
Fig 4: UV spectrum of CNP -λmax at 262 nm 
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The overlain spectrum of PNP is shown in fig-5.The absorbance corresponding to the 
concentration is tabulated in table-2. The five point calibration chart showed that the 
drug obeyed Beer’s law in the concentration range of 5–30 µg/mL. The linearity was 
assessed by the regression analysis as shown in the calibration chart. (fig-6) The 
correlation coefficient was found to be 1 which was within the limit. 
 
 
                 Fig 5: Overlain spectrum of PNP- λmax at 290 nm 
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                     Table 2: Absorbance of PNP at 290nm 
 
 
 
 
 
 
              *Each value is the mean of three determination 
 
 
             Fig 6: Calibration chart of PNP 
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S.No. 
Concentration 
(µg/mL) 
Absorbance at 
290nm* 
1 5 0.192 
2 10 0.384 
3 15 0.579 
4 20 0.769 
5 30 1.149 
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SAMPLE ANALYSIS:  
    The capsule dosage form contains CNP and PNP as separate tablets. So the 
drugs are estimated as separate entities. 
CINITAPRIDE 
            The formulation containing CNP was quantified. The sample concentration  
(8µg/mL) was so selected that it lies within the range of the linearity (4–20 µg/mL) 
of standard CNP. The analysis was performed in triplicate for three times and the 
mean of the three analyses was used for the calculation. The amount present and the 
percentage purity were calculated using the formula previously discussed. The 
percentage purity was found to lie between 99 and 101% and repeated analytical 
results confirms the precision of the developed method. The results of the sample 
analysis are shown in table-3 
      Table  3:  Results of Assay of CNP 
S.No. Label 
claim 
Amount present 
(in mg) ± SD* 
RSD 
% Purity 
± SD 
RSD 
1. 
3mg 
3.05 ± 0.000004 0.143 101.85 ± 0.145 0.00143 
2. 2.98  ± 0.000002 0.056 99.43 ± 0.056 0.00056 
3. 2.98  ± 0.000003 0.097 99.59 ± 0.097 0.00097 
        *Each value is the mean of three determinations. 
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PANTOPRAZOLE  
    The formulation containing PNP was quantified. The sample concentration 
(15 µg/mL) was so selected that it lies within the range of the linearity (5–30 µg/mL) 
of standard PNP. The analysis was performed in triplicate for three times and the 
mean of the three analyses was used for the calculation. The amount present and the 
percentage purity were calculated. The percentage purity was found to lie between 
99% and 101%.  The results of the sample analyses are shown in table - 4  
Table 4: Results of Assay of PNP 
S.No. Label 
claim 
Amount 
present        
(mg) 
± SD* 
RSD % Purity ± SD RSD 
1. 
40mg 
39.9 ± 0.00004 0.0917 99.75  ±  0.0914 0.0009 
2. 40.5 ± 0.00003 0.0675 101.29 ±  0.068 0.0007 
3. 40.6 ± 0.00005 0.135 101.43 ±  0.137 0.0014 
               *Each value is the mean of three determinations.   
 RECOVERY STUDIES 
The recovery studies were performed on spiked samples at three levels (20%, 40%, 
100%) using the standard addition technique. The results of the recovery analyses of 
CNP are tabulated in table-5 and that for PNP in table-6. The results of the recovery 
studies confirm the accuracy of the developed method. Thus, it assures that the 
developed method shows no interference by the sample matrix. 
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  Table 5: Results of Recovery Studies of CNP 
 
 
 
 
 
 
                   *Each value is the mean of three determinations. 
    Table 6: Results of Recovery Studies of PNP 
 
 
 
 
 
 
 
 
 
  
                    *Each value is the mean of three determinations. 
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20% 
3 
0.6 3.62 0.61 20.31 101.55± 0.18 0.0089 
40% 1.2 4.23 1.22 40.71 101.78± 0.45 0.0112 
100% 3.0 6.05 3.04 101.24 101.24± 0.64 0.0063 
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20% 
40 
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48.38 
 
8.05 
 
20.14 
 
100.69± .398 
0.02 
40% 16 
 
56.53 
 
16.3 
 
40.87 
 
101.34± 0.87 
0.02 
100% 80 79.6 39.27 
 
98.17 
 
100.47 ± 0.73 0.01 
Department of Pharmaceutical Chemistry Page 74 
 
METHOD B – AREA UNDER CURVE 
 The AUC (area under curve) method involves the calculation of integrated 
value of absorbance, between the two selected wavelengths λ1 and λ2. The 
wavelength range is selected on the basis of repeated observations so as to get the 
linearity between area under curve and concentration. The AUC between two 
selected wavelengths is digitally calculated and given by the in-built software in the 
UV spectrophotometer.  The spectra obtained in method A were used.  
CINITAPRIDE 
 The AUC for CNP was determined by taking 239.8nm as λ1 and 296.4nm as λ2 
in the spectra of the standard, sample and recovery studies. (fig-7) The AUC for 
different concentration are tabulated in table-7. Linearity was established by plotting 
AUC along X-axis and concentration along Y-axis 
 
Fig 7: AUC of CNP 
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             Table 7: Area Under Curves of CNP  
 
 
         
 
 
            *Each value is the mean of three determinations 
 
            Fig 8: Calibration chart – AUC vs Conc of CNP  
           The charts were found to be linear and the linearity assessed using regression 
analysis as shown in fig-8. The correlation coefficient was determined to be 0.9990 
for CNP. The sample AUCs were interpolated on the linearity charts to determine the 
concentrations. The amount present and the percentage purity were determined and 
y = 0.882x + 0.052
R² = 0.999
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AUC FOR CNP
S.No. Concentration(µg/mL) Area under curve* 
1 4 3.696 
2 8 7.314 
3 10 8.699 
4 12 10.559 
5 16 13.967 
6 20 17.894 
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tabulated in table 8. The percentage purity was found to lie between 100% and 
102%. The results of the repeated analysis   confirm the precision of the method.  
          Table 8: Results of Assay of CNP using AUC 
 
*Each value is the mean of three determinations. 
PANTOPRAZOLE 
 Similar to that of CNP,  the AUCs of the standard spectra of PNP were determined 
between 248.4 (λ1) and 314.0nm as (λ2) and shown in fig-9 and the AUC 
corresponding to concentration is given in table-9. 
 
Fig 9: AUC of PNP 
S.No. Label 
claim 
Amount present 
(in mg) ± SD* 
RSD % Purity ± SD RSD 
1. 
3mg 
3.04 ± .000028 0.0093 101.57 ± 0.945 0.0093 
2. 3.02 0.000019 0.0062 100.68 ± 0.630 0.0062 
3. 3.02  ± .000019 0.0062 100.68 ± 0.630 0.0062 
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           Table  9: Area under Curves  of PNP 
 
 
 
 
 
                        *Each value is the mean of three determinations 
      
           Fig 10: Calibration chart – AUC vs Conc of PNP 
The linearity of response was assessed using regression analysis. The correlation 
coefficient was determined to be 0.9990 for PNP shown in fig-10. The sample AUCs 
were interpolated on the linearity charts to determine the concentrations. The amount 
present and the percentage purity were determined and shown in table-10. The 
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AUC FOR PNP
S.No. Concentration (µg/mL) 
Area under curve* 
1 5 4.707 
2 10 9.046 
3 15 14.551 
4 20 18.984 
5 30 28.539 
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percentage purity was found to lie between 99% and 100%.  From the SD and RSD 
values obtained, precision of the developed method is confirmed. 
           Table 10: Results of Assay PNP using AUC 
S.No. Label 
claim 
Amount present 
(mg) ± SD* 
RSD % Purity ± SD % RSD 
1. 
40mg 
40.1 ±0.0004 0.0094 100.35 ± 0.939 0.009 
2. 40.1 ± .0002 0.0054 100.35 ± 0.542 0.005 
3. 39.6 ± .0002 0.0047 99.02 ± 0.469 0.0047 
            *Each value is the mean of three determinations. 
 
RECOVERY STUDIES (CNP&PNP) 
The AUC of the spectra obtained for the recovery studies (spiked samples at three 
levels 20%, 40%, 100%) of the samples  ( both CNP and PNP) were interpolated on 
the linearity chart of the respective drugs and the concentrations were determined. 
The recovery percentage was calculated using the formula 
=;42>;:? % 
:ABA3<C <D263E F E<3G<:G 9D263E
E<3G<:G 9D263E
( 100 
 
 The results of recovery studies and recovery percentage for both CNP and PNP are 
tabulated in table-11&12 respectively.  
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        Table 11: Results of Recovery Studies of CNP using AUC 
        *Each value is the mean of three determinations. 
        Table 12: Results of Recovery Studies of PNP using AUC 
 
 
 
 
 
        *Each value is the mean of three determinations. 
The results of the recovery studies shows recovery % of 98 to 102% which is 
within the limit and the low RSD value confirms that the developed method is 
accurate for both CNP and  PNP. Thus the developed method is accurate and 
precise, irrespective of the sample matrix. 
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0.6 3.67 0.6 20.13 100.66 ± 0.59 0.029 
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100% 3.0 6.1 3.03 100.95 100.95 ± 0.29 0.002 
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20% 
40
mg 
8 48.03 8.15 20.38 101.10 
± 0.313 0.0153 
40% 16 56.00 16.13 40.31 100.80 
± 0.626 0.0155 
100% 80 79.09 39.21 98.02 98.02 ± 0.717 0.0073 
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METHOD C – SECOND DERIVATIVE (Beckett, 2007) 
Derivative spectrophotometry involves the conversion of normal spectrum to 
its first, second or higher derivative spectrum. The second derivative (D2) spectrum 
is the plot of the curvature of the D0 spectrum or a plot of d2A/ dλ2 against λ. The 
characteristic of the second order spectra is that it represents a negative maximum 
just at the original λ max of the analyte. The amplitude of the negative maxima 
downwards is directly proportional to the concentration of the analyte.  
CINITAPRIDE 
The zero order spectra of CNP obtained in method A were derivatized to the 
second order derivative spectra. CNP shows negative maxima at 262 nm which is the 
λ max of CNP. The overlain second derivative spectra are shown in fig-11.  
 
            Fig 11: Overlain II Derivative spectrum of CNP  
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Graph was plotted using amplitude of the negative maxima along X-axis and concentration 
along Y –axis as shown in table-13 and fig-12. A linear graph obtained  was analysed using 
regression analysis method to determine the linearity of amplitude maxima with 
concentration. It reveals the correlation coefficient to be 0.999.  
                     Table 13:  Amplitude and Concentrations-CNP  
S.No. Concentration(µg/mL) Amplitude* 
1 4 2 
2 8 4 
3 10 4.9 
4 12 5.9 
5 16 7.7 
6 20 9.6 
              *Each value is the mean of three determinations 
            
       Fig 12: Calibration chart –Amplitude vs. Conc-CNP 
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The zero order spectrum of the sample was derivatized to second order. The sample 
concentrations were arrived by interpolation of their amplitudes in the linearity chart. 
The amount present was calculated and presented in table-14. The percentage purity 
of CNP was determined to lie between 99% and 102%. The assay was conducted 
thrice in triplicate. The results of the repeatability confirm that the method is precise. 
Table 14: Results of Assay CNP using II derivative method 
S.No. Label 
claim 
Amount present  
(in mg) ± SD* 
RSD % Purity ± SD % RSD 
1. 
3mg 
 
3.05  ± 0.000014 
 
0.0046 101.91 ± 0.472 0.0046 
2. 
 
2.99  ± 0.000009 
 
0.0031 99.80 ± 0.315 0.0031 
3. 
 
2.99  ± 0.000014 
 
0.0047 99.91 ± 0.472 0.0047 
*Each value is the mean of three determinations. 
 
PANTOPRAZOLE 
 Similarly, the zero order spectrum of PNP was derivatized to obtain second 
derivative spectrum. It showed a negative maximum at 290 nm. The overlain second 
derivative spectrum of PNP is shown in fig-13. Linearity was established using 
amplitude against concentration. The amplitudes of the negative maxima are given in 
table-15.  
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                        Table 15:  Amplitude and Concentrations-PNP  
 
 
 
 
 
 
                  *Each value is the mean of three determinations. 
                    
       
                          Fig 13: Overlain II Derivative spectrum of PNP  
 
S.No. Concentration (µg/mL) 
Amplitude* 
1 4 0.9 
2 8 1.8 
3 10 2.2 
4 12 2.6 
5 16 3.5 
6 20 4.3 
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The linearity chart is shown in fig-14, which shows the correlation coefficient to be 
0.9996.  
               
           Fig 14: Calibration chart –Amplitude vs. Conc-PNP 
 
Similarly, the sample spectrum was derivatized to the second order. The 
amplitude of the negative maxima was interpolated on the linearity chart to 
determine the sample concentration. The results of the analysis are shown in table-
16. The percentage purity of the CNP was determined to lie between 99% and 102%. 
The precision of the method was analysed by conducting the assay thrice in 
triplicate. The results of the repeatability studies show that the method is precise. 
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  Table 16: Results of Assay PNP using II Derivative method 
S.No. Label 
claim 
Amount 
present (mg) 
± SD* 
RSD % Purity ± SD RSD 
1. 
40mg 
 
39.5 ± 0.0001 
 
0.0031 98.8 ± 0.313 0.0030 
2. 
 
40.0 ± .00009 
 
0.0023 100.02 ± 0.234 0.0023 
3. 
 
40.0 ± .00019 
 
0.0046 100.02 ± 0.469 0.0047 
             *Each value is the mean of three determinations. 
 
RECOVERY STUDIES (CNP&PNP) 
The recovery studies were performed for CNP and PNP. Recovery studies 
were performed based on stanadard addition technique. The zero order spectra 
obtained for recovery studies (20%, 40%, and 100%) in method A were derivatized.  
The amplitudes of the negative maxima were interpolated on the respective second 
derivative linearity charts and the concentrations were determined. Using the 
concentration, the recovery percentage was determined and tabulated in table-17 for 
CNP and table-18 for PNP. The low RSD value indicates that recovery was 
appreciable and confirms that the interference due to sample matrix is negligible. 
Thus the method is accurate for both CNP and PNP.  
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     Table 17: Results of Recovery Studies of CNP - II Derivative method 
              
*Each value is the mean of three determinations. 
 
  Table 18: Results of Recovery Studies of PNP - II Derivative method 
 
 
 
 
 
 
 
 
 
                                              
*Each value is the mean of three determinations. 
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20% 
40 
mg 
8 47.94 8.09 20.21 101.07±0.313 0.0155 
40% 16 56.00 16.15 40.37 
 
100.93±0.626 
 
0.0155 
100% 80 80.50 40.70 101.74 101.74 ± .939 0.0092 
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Table 19: Optical parameters of CNP and PNP-UV Spectrophotometry 
S.No Optical Parameter 
Cinitapride Pantoprazole 
Method Method 
  A B C A B C 
1. 
Wavelength 
λmax 
 
262 nm 
 
262nm 262nm 290 nm 290nm 290nm 
2. 
Molar 
absorptivity 
 
22557.89 
 
--- --- 14746.97 ---- ---- 
3. Beer’s law limit µg/ml 
4-20 
 
4-20 
 
4-20 
 
5-30 5-30 5-30 
4. Regression 
equation 
y = 
0.056x + 
0.000 
y = 
0.882x + 
0.052 
y = 
0.478x + 
0.085 
y = 
0.038x + 
0.001 
y = 
0.955x - 
0.095 
y= 
0.215x 
+0.035 
5. 
 
Slope 0.05602 0.882 0.478 0.03815 0.955 0.215 
6. Intercept 
 
0.00029 0.052 0.085 0.001 -0.095 0.035 
7. Correlation 
coefficient 1.0 
0.9990 
 
0.999 1.000 
 
0.9990 
 
0.999 
8. Sandell’s 
sensitivity 
0.0178 
 
---- ---- 0.0260 ---- ---- 
9. LOD 0.03366 
 
--- --- 0.4144 ---- ---- 
10. LOQ 0.10200 
 
---- ---- 1.2560 ---- --- 
11. RSD 0. 4710 
 
0. 9901 
 
1.1310 
 
0.8022 
 
0.9548 
 
0.4782 
 
 
 
 
Department of Pharmaceutical Chemistry Page 88 
 
II. VISIBLE SPECTROPHOTOMETRIC METHOD 
CINITAPRIDE (Chand Pasha, et al., 2010) 
METHOD A USING ETHYL ACETO ACETATE (EAA) 
The colorimetric method for estimation of CNP is based on the diazotization
 
of the primary aromatic amino group in CNP. The diazotized CNP is then coupled 
with EAA in alkaline media. The diazotisation of drugs containing free amino group 
is a well known reaction.  
In this method the primary aromatic amino group in CNP is diazotized using 
sodium nitrite solution and hydrochloric acid. Diazonium compounds are unstable 
and would decompose at elevated temperature, hence temperature was maintained 
below 5°C until the addition of sodium hydroxide. The amino group is converted 
into diazonium salt which on treatment with EAA undergoes coupling reaction to 
form a diazo couple. EAA is the coupling agent. The active methylene group present 
in it undergoes coupling reaction in alkaline condition. The diazo couple formed is 
waters soluble and coupling reaction takes place only in alkaline medium which is 
provided by the addition of sodium hydroxide solution. The diazo couple is reddish 
orange in colour for which the maximum absorbance was observed at 392.5 nm. The 
stability of the colour was determined by measuring the absorbance of the solutions 
at 15 minute intervals. The absorbance was found to stable for 3 hrs 15 minutes, after 
which the absorbance started decreasing. Thus the stability of the diazo couple was 
determined to be 3 hrs 15 minutes.  So, all the studies were performed within 3 hrs of 
formation of the diazo couple. The reaction mechanism is given below: 
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REACTION MECHANISM 
  
     
 
 
 
 
    NANO2/HCl 
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                  Diazonium salt of Cinitapride 
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 OPTIMISATION OF THE REAGENTS 
              Diazotization and complexation reaction condition: 
The conditions for the diazotization (Shahar Yar M ) are well established to take 
place  at 0-5°C. An elevated temperature leads to incomplete diazotization and 
decomposition of diazotized compound (Jim Clark) which could be assessed by the 
non linear response of the diazotized mixture in UV spectrophotometry at 
410nm.The volume and strength of the sodium nitrite and hydrochloric acid used 
was optimized. It was found that an increase or decrease from 1-2mL and 1-4% of 
sodium nitrite brought about no change in response or very less absorbance. By trial 
and error it was established that 2 mL each of 2% sodium nitrite solution, 0.5M 
hydrochloric acid and 2% EAA were found to give good linear relationship between 
absorbance and concentration. Any change in the volume or strength of the above 
reagents showed deviation from the linearity. Similarly the strength and volume of 
sodium hydroxide were also optimized.  It was observed that 1mL of 1M sodium 
hydroxide was optimal to ensure complete complexation and good colour intensity. 
Finally the concentration of the analyte was also studied. Lower the concentration 
(below 10µgm) lower was the colour intensity as a result, the absorbance was very 
less and did not show significant difference.  Higher concentration (above 60µg/mL) 
showed deviation from the linearity. The absorbance of the couple with respect to 
concentration is shown in table-20. The absorbance gradually increased with respect 
to concentration 
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              The overlain spectrum of CNP –EAA diazo couple is shown in fig-14. 
                
                     Fig 15:     Overlain spectrum of CNP –EAA diazo couple 
                       
                        Table 20 : Absorbance of CNP –EAA complex  
 
                                    
 
 
 
 
                              * Each value is the mean of three determination 
S.No. Concentration (µg/mL) 
Absorbance* 
at  392.5 nm 
1 10 0.247 
2 20 0.424 
3 30 0.644 
4 40 0.882 
5 50 1.064 
6 60 1.265 
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Thus 10-60µg/mL of CNP obeyed Beer’s law and was selected for the study. 
The correlation coefficient was found to be 0.999 as shown in fig-16. Thus 10-
60µg/mL of CNP obeyed Beer’s law and was selected for the study. The correlation 
coefficient was found to be 0.998 as shown in fig-16. The linearity chart shows that 
the absorbance linearly increased with concentration. The linearity chart is used for 
the estimation of the drug in formulation. 
  
Fig 16: Calibration chart of CNP – EAA 
ANALYSIS OF FORMULATION 
About 30 µg/mL concentration of formulation was similarly analysed to that of the 
standard drug and the amount present and percentage purity was calculated presented 
in table- 21. Precision of the developed method has been ascertained by the 
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reproducibility of the assay results, when repeated thrice in triplicate. Since the 
results were found to be reproducible, the method is precise. 
    Table 21: Results of assay of CNP using EAA 
S.No
. 
Label 
claim 
Amount present  
(mg) ± SD* RSD % Purity ± SD RSD 
1. 
3mg 
2.98  ± 0.000010 0.0034 99.17 ± 0.3373 0.0034 
2. 2.99  ± 0.000008 0.0026 99.54 ± 0.2654 0.0026 
3. 2.99  ± 0.000020 0.0068 99.17 ± 0.472 0.0068 
* Each value is the mean of three determination 
METHOD B — USING ACETYL ACETONE (AAC) 
This method is also based on the diazotisation of CNP followed by coupling 
of the diazonium salt with a diketone. The diketone is acetyl acetone which acts as a 
coupling agent. The amino group is converted into diazonium salt which on 
treatment with AAC forms a diazo couple. The active methylene group in AAC 
undergoes coupling with the nitrogen of the diazo group in CNP. The coupling 
reaction takes place only in an alkaline medium which is provided by the addition of 
sodium hydroxide solution. The complex is reddish orange in colour for which the 
maximum absorbance was observed at 399nm. The mechanism of the reaction is 
hown below. The stability of the diazo couple was found to be 3 hrs 15 minutes. The 
mechanism of the complexation is shown in the next page. 
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REACTION MECHANISM 
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              Diazo couple of CNP –AAC  (reddish orange chromogen) 
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OPTIMISATION OF THE REAGENTS 
  Diazotization and complexation reaction condition: 
The optimizations of diazotization reagents are the same as that for the 
method A. In this method also 2mL of 2% sodium nitrite solution and 2ml of 0.5 M 
hydrochloric acid was sufficient for diazotising CNP completely at 0-5° C. By trial 
and error, it was established that 2mL of 2% AAC were found to give good linear 
relationship between absorbance and concentration. Any change in the volume or 
strength of AAC showed deviation from the linearity. Similarly the strength and 
volume of sodium hydroxide were also optimized.  It was observed that 1mL of 1M 
sodium hydroxide was optimal to ensure complete coupling and good colour 
intensity. Below 0.5 ml of 1M sodium hydroxide, the intensity of colour of the diazo 
couple was not good and above 1 ml there was no change in the colour intensity. 
Finally the concentration of the analyte was also studied. Lower the concentration 
(below 10µgm) lower was the colour intensity as a result the absorbance was very 
less and did not show much difference in the absorbance. Higher concentration 
(above 50µg/mL) showed deviation from the linearity. Thus 10-50µg/mL of CNP 
obeyed Beer’s law (table-22 & fig-18) and was selected for the study.  The 
correlation coefficient was found to be 0.996.  
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The overlain spectra of CNP - AAC is shown in fig-17.  
             
                 Fig 17: Overlain spectrum of CNP-AAC diazo couple 
 
     Table 22 : Absorbance of CNP –AAC  
S.No. Concentration (in µg/mL) 
Absorbance* 
1 10 0.169 
2 20 0.330 
3 30 0.494 
4 40 0.651 
5 50 0.776 
*Each value is the mean of three determinations. 
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The linearity chart of CNP-EAA complex is shown in fig -18. It shows that 
the absorbanbce linearly increase with concentration. 
 
           Fig 18: Calibration chart of CNP – AAC 
 
ANALYSIS OF FORMULATION 
Sample concentration was so selected for the study such that the final 
concentration (20 µg/mL) for the complexation lies within the Beer’s range. Similar 
to the standard drug, the sample was allowed to undergo diazotization and coupling 
reaction. The percentage purity was calculated and presented in table–23.  The 
percentage purity was found to lie between 99.8 to 101.9%.The precision studies was 
performed by analysing sample thrice in triplicate. The results of the repeatability 
studies  ensure that the method is precise. 
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               Table 23.  Results of assay CNP using AAC 
 
 
 
 
                    
*
*
 
*Each value is the mean of three determinations. 
 
RECOVERY STUDIES (CNP- Method A & B) 
Accuracy of the developed method was determined by the usual recovery 
studies. The recovery studies were performed by standard addition technique. It 
involves the addition of standard drug to the preanalysed sample. The resultant 
sample was then subjected to colorimetric reaction as discussed in method A & B 
separately. The results are shown in the table–24 & 25 for method A & B 
respectively. The results of recovery studies were found to lie between 98-102 % , 
for both methods which was within the limit. The results of the recovery studies 
indicate that the method developed is devoid of any interference by the sample 
matrix or excipients in the formulation.         
 
S.No. Label 
claim 
Amount present  
(in mg) ± SD* 
 
  RSD 
 
% Purity ± SD 
 
RSD 
1. 
3mg 
3.02  ± 0.000027 0.0090 101.91 ± 0.472 0.0046 
2. 2.94 ± 0.000035 0.0118 99.80 ± 0.315 0.0031 
3. 3.05  ± 0.000044 0.0147 99.91 ± 0.472 0.0047 
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              Table 24: Results of Recovery studies (CNP-EAA) 
       
 
 
 
 
 
 
 
               *Each value is the mean of three determinations 
 
              Table 25 : Results of Recovery studies ( CNP-AAC) 
         
 
 
 
 
 
 
                   
 
 
 
                    *Each value is the mean of three determinations. 
 
Ex
pe
ct
ed
 
%
 
 
R
ec
o
v
er
y 
Amount of drug 
added 
(mg) Total 
amount 
assayed 
(mg)* 
Amount 
recovered 
(mg) 
Assessed 
% 
Recovery 
% Recovered 
± S.D RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
27 % 
3mg 
0.8 3.8 0.8 27.62 102.17  ± 0.725 0.0260 
50 % 1.5 4.44 1.50 
 
48.91 
 
98.15 ± 0.515 0.0105 
100 % 3.0 5.91 2.90 100.95 98.11± 0.389 0.0039 
Ex
pe
ct
ed
 
%
 
R
ec
o
v
er
y 
Amount of 
drug added 
(mg) Total 
amount 
assayed 
(mg)* 
Amount 
recovere
d 
(mg) 
Assessed 
% 
Recovery 
%  Recovered  
± S.D RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
20% 
3mg 
 
0.6 3.57 0.59 
 
19.82 
 
98.50 ± 0.380 0.0191 
 40 % 1.2 4.17 1.19 
 
39.80 
 
99.38 ± 0.900 0.0225 
100 % 
 
3.0 
 
5.97 
 
 
2.99 99.76 100.07± 1.69 0.0170 
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 PANTOPRAZOLE (Basavaiah K., et al., 2007; Adnan A., et al., 2002) 
The visible or colorimetric determination of pantoprazole is based on the 
oxidation of PNP to its sulphone derivative by by insitu generated bromine followed 
by determination of unreacted bromine by two different reaction schemes. In method 
A, the residual bromine is treated with excess of iron (II), and the resulting iron (III) 
is complexed with thiocyanate and measured at 470 nm. Method B involves treating 
the unreacted bromine with a measured excess of iron (II) and remaining iron (II) is 
complexed with 1,10-phenanthroline at a raised pH, and measured at 510 nm. In both 
methods, the amount of bromine reacted corresponds to the amount of PNP.  
METHOD A- USING 1, 10- PHENANTHROLINE 
The colorimetric estimation of PNP is based on the oxidation of PNP by the 
insitu liberation of bromine during the reaction between excess bromate-bromide and 
hydrochloric acid.  Pantoprazole is oxidized to form the sulphone analogue. The 
unreacted bromine left after oxidation of PNP is determined indirectly by the 
oxidation of large excess FAS to ferric ammonium sulphate. The unreacted FAS then 
treated with 1, 10-phenanthroline form a blood red complex of FAS - 1, 10-
phenanthroline (ferroin) which is a very well known  complexation reaction used for 
the estimation of iron in the ferrous state. The complex shows λmax at 510 nm. 
When a known excess amount of bromate-bromide mixture is allowed to react with 
increasing amount of PNP, there occurs decrease in the amount of bromine for 
oxidation of FAS to ferric ammonium sulphate. Thus, an increase in the 
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concentration of the FAS, available for complexation with 1, 10-phenanthroline is 
observed from the increase in the absorbance, as shown by the slope in the 
calibration chart (fig-20). Since the complex is formed and is stable only in alkaline 
media, ammonia solution is used.  
 
 REACTION MECHANISM: 
I. Oxidation 
            KBrO3 + 5KBr + 6HCl                                              6 KCl +  3Br2(g)  + 3H2O 
            (potassium bromate-bromide)                                              bromine 
                                  
    
                    Pantoprazole                                 Br2         (o)        
 
 
                                                                         Oxidised  form of panatoprazole 
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II. Complexation (Vogels., 2007)        
 
                  Fe 2+  +   Br2  (unreacted)                (o)                      Fe 3+  +   2 Br   
                      (ferrous)                                                                (ferric)                                      
                    Fe 2+   +                             
N
N
F e 2 +
N
N
N
N
 
                         (ferrous)               1,10 Phenanthroline                          Fe[(C12H8N2)3]2+ 
                        Red chromogen (ferroin) 
 
OPTIMISATION OF THE REAGENTS 
 The strength and volume of hydrochloric acid and bromate-bromide mixture was 
optimized. Any change in the volume of the reagent resulted in either insufficient 
liberation or large excess of bromine which did not give any good response. Thus 
1ml of 5M hydrochloric acid and 2ml of bromate –bromide mixture and 2ml of FAS 
was selected for the complete reduction of the unreacted bromine. Moreover, 2mL of 
1, 10- phenanthroline was required for the complete complexation of the excess, 
unreacted FAS.  The complex is formed only in an alkaline medium which is 
provided by the addition of ammonia solution. About 2 ml of ammonia solution was 
sufficient to neutralize and slightly raise the pH of the solution at which the 
complexation is complete. Any more increase in volume of the ammonia solution, 
N N
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drastically increases the pH of the solution resulting in the instability of the complex. 
The chromogen was red in colour which showed a maximum absorbance at 510 nm. 
Higher concentration of the analyte, required very high concentration and large 
excess of the bromate-bromide mixture.  So the linearity of response with respect 
concentration of standard PNP was established using a low concentration range of 
PNP.  Thus, beer’s range was determined to be 1.2-5.4µg/mL. (table-26 & fig 21)  
The estimation of PNP by the above method was also performed within the Beer’s 
range. The amount of the reagents, the condition of the reagents and the order of the 
addition of reagents were maintained throughout the analysis of the sample.  The 
overlain spectrum is shown in fig-19. 
 
                 Fig 19 : Overlain spectra  PNP using 1,10- phenanthroline  
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Table 26 : Absorbance of PNP  using 1,10-phenathroline 
S.No. Concentration (in µg/mL) 
Absorbance* 
1 1.2 0.160 
2 2.4 0.318 
3 3.6 0.466 
4 4.8 0.622 
5 5.4 0.703 
                 *Each value is the mean of three determinations 
 
 
                 Fig 20: Calibration chart of PNP using 1,10-phenanthroline 
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ANALYSIS OF FORMULATION 
The concentration of the sample was prepared such that it lies within the 
linearity range. The optimized reagents and conditions were applied for the sample 
analysis. The results of the sample analysis are presented in table–27. The percentage 
purity was determined and found to lie between 98.62 and 99.75%. The results were 
reproducible, when the assay was performed thrice in triplicate. So the method is 
said to be precise. 
            Table 27: Results of assay PNP– 1, 10-phenanthroline 
S.No. Label 
claim 
Amount 
present (mg) 
± SD* 
RSD % Purity ± SD RSD 
1. 
40mg 
39.5 ± 0.0002 0.9898 98.62 ± 0.731 0.9899 
 
2. 39.5 ± 0.00028 0.9949 98.70 ± 0.710 0.9941 
 
3. 39.9 ± 0.00026 0.9943 99.71 ± 0.665 0.9943 
 
            *Each value is the mean of three determinations. 
METHOD B – USING AMMONIUM THIO CYANATE (ATC) 
The colorimetric estimation of PNP is based on the oxidation of PNP by the 
insitu liberation of bromine during the reaction between excess bromate-bromide and 
hydrochloric acid. The unreacted bromine left after oxidation of PNP is determined 
indirectly by the oxidation of FAS to ferric ammonium sulphate. This in turn is 
complexed with ammonium thiocyanate to form a blood red complex of ferric thio 
cyanate which is a very well known reaction. The complex shows λmax at 477nm.  
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REACTION MECHANISM: 
I. Oxidation 
            KBrO3 + 5KBr + 6HCl                                              6 KCl + 3Br2 + 3H2O 
      (potassium bromate-bromide                                        potassium    +    bromine 
            +  hydrochloric acid)                                                chloride                             
                                                                   
     
       Pantoprazole                                          Br2   (O) 
                                                                           
II. Complexation (Vogels., 2007)                    Oxidised  form of panatoprazole 
                                                  
            Fe 2+  +   Br2  (Excess)             (o)                       Fe 3+  +2 Br  - 
(ferrous)                                                         (ferric) 
 
Fe 3+  +  3SCN                                              Fe(SCN)3 
                                                             Red chromogen  ( ferric thiocyanate) 
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When a known excess amount of bromate-bromide mixture is allowed to 
react with increasing amount of PNP, there occurs decrease in the amount of 
bromine for oxidation of FAS to ferric ammonium sulphate. Thus, the decrease in the 
concentration of the complex is observed from the decreasing absorbance, resulting 
in a negative slope in the calibration chart fig-22. The overlain spectrum is shown 
(fig-21) 
 
               Fig 21 : Overlain spectra  PNP – ATC at 477nm 
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   OPTIMISATION OF THE REAGENTS 
The strength and volume of the redox reagents viz; hydrochloric acid, 
bromated-bromide mixture, FAS was the same as that for method A.Thus 1ml of 5M 
hydrochloric acid and 2ml of bromate –bromide mixture and 2ml of FAS was 
selected for the completion of the redox reaction. Moreover, 1mL of 3 molL-1 
ammonium thio cyanate was required for the complete complexation of oxidised 
ferric ammonium sulphate to ferric thio cyanate. The ferric thio cyanate complex is 
blood red in colour and was found to be stable for 3 hrs. It showed maximum 
absorbance at 470 nm. Higher concentration of the analyte, required very high 
concentration and large excess of the bromate-bromide mixture. The above 
developed method obeyed Beer’s law at the concentration of 0.4-2.4 µg/ml of PNP 
which showed a gradual decrease in the concentration of the bromine by the linear 
negative slope.(table-28)  
      Table 28: Absorbance of PNP – ATC 
 
S.No. Concentration (in µg/mL) Absorbance* 
1 0.4 0.315 
2 0.8 0.276 
3 1.2 0.216 
4 1.6 0.164 
5 2.0 0.111 
6 2.4 0.061 
*Each value is the mean of three determinations. 
 
Department of Pharmaceutical Chemistry Page 109 
 
This is also evidenced by the negative slope of the calibration curve. (fig- 22) 
The correlation coefficient was within the limit as 0.998. 
                  
          Fig 22: Calibration chart of PNP- ATC 
ANALYSIS OF FORMULATION 
 The sample concentration was so selected that it lies in the linearity range. It 
was analysed similar to that of the standard drug. The results of the assay and 
percentage purity are shown in the table-29. The percentage purity was determined to 
be between 98 to 100%. The precision of the developed method has been analysed 
by performing the assay thrice in triplicate. The results of the repeatability studies 
show that the method is precise. 
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             Table  29: Results of assay of PNP  using ATC 
S.No. Label 
claim 
Amount 
present(mg)  
± SD* 
RSD % Purity ± SD RSD 
1. 
40mg 
40.2 ± 0.00059 0.983 100.40 ± 1.49 0.9834 
2. 39.6 ± 0.00029 1.009 98.07 ± 0.746 1.0099 
3. 39.4 ± 0.00023 0.9927 98.47 ± 0.593 0.9927 
             *Each value is the mean of three determinations 
 
RECOVERY STUDIES (PNP- Method A & B) 
 
Accuracy of the developed method was determined by the usual recovery 
studies. The recovery studies were performed by standard addition technique. It 
involves the addition of standard drug to the preanalysed sample. The resultant 
sample was then subjected to colorimetric reaction as discussed in method A & B 
separately. The results are shown in the table-30 & 31 for method A & B 
respectively. The results of recovery studies were found to lie between 98-102 %, for 
method- A and for method–B, 99-102%, which was within the limit. The results of 
the recovery studies indicate that the method developed shows no interference by the 
sample matrix or excipients in the formulation.       
  The optical parameters of CNP and PNP BY colorimetric methods are 
presented in table-32 
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Table 30: Results of recovery studies PNP – 1,10 - phenanthroline 
 
Ex
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%
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y 
Amount of 
drug added 
in mg 
Total 
amount 
assayed 
(mg)* 
Amount 
recovered 
(mg) 
Assessed 
% 
Recovery 
% Recovered ± 
S.D RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
20% 
40 
mg 
8 47.52 8.07 20.17 100.84 ± 0.152 0.0075 
40% 16 59.09 19.6 49.09 
 
98.18± 1.14 
 
0.0234 
100% 80 80.25 40.8 101.99 101.99± 0.79 0.0077 
             *Each value is the mean of three determinations. 
 
Table 31: Results of recovery studies for PNP-ATC 
 
Ex
pe
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ed
 
%
 
re
co
v
er
y 
Amount of 
drug added 
in mg Total 
amount 
assayed 
(mg)* 
Amount 
recovered 
(mg) 
Assessed 
% 
Recovery 
% Recovered ± 
S.D RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
25% 
40
mg 
10 50.44 11.0 27.62 102.12± 1.180 0.1225 
50% 20 58.45 19.1 47.66 99.5± 1.180 0.0524 
100% 40 80.50 41.1 102.78 102.78± 1.180 0.0101 
              *Each value is the mean of three determinations. 
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Table 32: Optical parameters of CNP and PNP by colorimetry 
S.No Optical Parameter 
 
Cinitapride 
 
Pantoprazole 
 
Method A 
(EAA) 
Method B 
(AAC) 
Method A 
(1,10-PHT) 
Method B 
(ATC) 
1. Wavelength λmax 392.5 nm 399nm 510nm 477 nm 
2. Molar absorptivity 8837.83 6571.97 5022.02 95581.60  
3. Beer’s law limit 
(µg/mL) 
10-60 
 
10-50 
 
1.2-5.4 0.4 -2.4 
 
4. Regression 
equation 
y=0.021x+ 
0.006 
y=0.015x + 
0.011 
y=0.129X + 
0.002 
y=-0.1297X + 
0.372 
5. 
 
Slope 0.021 0.015 0.129 -0.1297 
6. Intercept 0.006 0.011 0.002 0.372 
 
7. 
Correlation 
coefficient 
0.999  
0.998 
0.999 0.998 
8. Sandell’s 
Sensitivity 
0.046 
 
0.061 0.008 0.13 
9. LOD 4.40 
 
5.18 0.234 18.9 
10. LOQ 13.33 
 
15.68 0.707 57.4 
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III. RP- HPLC METHOD 
An effort has been made to develop simple, precise, cost- effective and 
accurate methods for the estimation of Cinitapride and Pantoprazole in bulk and 
tablet dosage form. 
Detector wavelength 
 A solution of 10 µg/ml of CNP standard drug in mobile phase was scanned 
in the UV region to determine the detector wavelength. It was observed that CNP 
showed λmax at 262 nm. Hence this was selected as the detecting wavelength for the 
estimation of CNP by HPLC. Similarly, 10 µg/ml solution of PNP in mobile phase 
showed λmax at 290 nm. So, 290 nm was selected for the estimation of PNP by 
HPLC. 
Reverse phase-HPLC 
 The analytes are more polar in nature RP-HPLC method was selected. 
Optimization of the chromatographic condition 
The chromatographic condition was optimized using the standard drugs CNP 
and PNP. The optimization procedure involves the optimization of mobile phase in 
relation to its compatibility to the system suitability parameters as per ICH 
guidelines. 
By trial and error method the mobile phase containing acetonitrile, methanol 
and phosphate buffer (pH-7) in the ratio of 40:20:40 % v/v was selected for the 
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study.The mobile phase of pH-7 and flow rate of 2 ml/minute was selected for the 
study of CNP and PNP. Thus it was observed that the optimized chromatographic 
condition was common for both CNP and PNP which is the main advantage of the 
developed method.  
System suitability parameters 
The system suitability parameters for both the drugs CNP and PNP in the 
optimized chromatographic condition were calaculated and present in the table-33. 
All the values were compared with the standard values given by ICH guidelines and 
found to be compatible. The number of theoretical plates for CNP and PNP was 
found to be 6497 and 5091 respectively which confirms the good efficiency of the 
column for the drugs and nature of mobile phase. 
Table 33: System suitability parameters for CNP and PNP 
 
 
 
 
 
 
 
 
S.no Parameter Cinitapride Pantoprazole 
1. Theoretical Plates 6497 5091 
2. Tailing factor 0.93 1.32 
3. Capacity factor 0 0 
4. Temperature of the column ambient ambient 
5. Retention time 6.5 minutes 3.5 minutes 
6. Correlation coefficient (r2)   1 1 
7. Correlation coefficient (r2)   1 1 
8. Limit of Detection (LOD) (µg/ml) 1.5 1.9 
8. Limit of Quantitation (LOQ) (µg/ml) 5.3 5.8 
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The optimized chromatogram of CNP and PNP is shown in fig 23 & 24 
respectively. The chromatograms shows the retention time (Rt) of CNP to be 6.5 
minutes and that of PNP to be 3.5 minutes.  
               
                        Fig 23: Chromatogram of CNP (Rt - 6.5 minutes) 
              
                    Fig  24: Chromatogram of PNP (Rt- 3.5 minutes) 
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ESTABLISHMENT OF LINEARITY 
Linearity of the drug’s concentration with respect to the instrumental 
response (peak area) was established for both CNP and PNP. The peak areas with 
respect to concentration are presented in the table-34 and 35.  A calibration chart was 
plotted using concentration along X –axis and peak area along Y-axis. The linearity 
of response under the optimized chromatographic condition was analysed using 
regression analysis. CNP obeyed Beer’s law at 84-132µg/ml and PNP at 140-
220µg/ml. The correlation coefficient was found to be equal to 1 for both CNP and 
PNP which is shown in the respective linearity chart.( fig-25and 26). 
 LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION: 
The LOD and LOQ were determined from the average of the three 
determinations of the slope and standard errors of estimate of the respective linearity 
charts. The LOD was found to be 1.5 µg/ml for CNP and 1.9µg/ml for PNP; LOQ as 
5.3 µg/ml and 5.8µg/ml for CNP and PNP respectively. 
  Table  34:  Peak area of CNP 
S.No. Concentration  
µg/mL 
Peak area 
1. 84 1670.30 
2. 96 1863.70 
3. 108 2110.90 
4. 120 2325.40 
5. 132 2571.90 
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Fig 25 : Calibration chart of CNP  - HPLC 
 
Table 35: Peak area of PNP 
S.No. Concentration  
(µg/mL) 
Peak area 
1. 140 3964.82 
2. 160 4442.76 
3. 180 4966.63 
4. 200 5542.18 
5. 220 6082.93 
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           Fig 26 : Calibration chart of CNP- HPLC  
ANALYSIS OF FORMULATION 
 The formulation of CNP and PNP was quantified using the optimized 
chromatographic condition. As the combined dosage form contains CNP and PNP as 
individual tablets, they are analysed separately.  
The concentrations of the dosage forms in mobile phase was so selected that 
it lies in the respective linearity range. 20 µl of the samples were injected separately, 
CNP was detected at 262 nm and PNP at 290 nm; the chromatograms were recorded 
(figure-27 and 28). The sample was analysed thrice. The percentage purity of the 
CNP was determined to be 99% to 101% which is represented in table-36. Similarly 
the percentage purity of the sample PNP was determined to be 1005 to 101% which 
is represented in table-37 
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                  Fig 27: Chromatogram of   Sample CNP 
 
              Fig 28: Chromatogram of   Sample PNP 
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    Table 36: Results of Assay of CNP 
S.No. Label 
claim 
Amount 
present (mg) 
%purity SD RSD 
1.  
3mg 
2.97 
 
99.16 
 
± 0.7856 
 
0.0078 
2. 2.97 
 
99.16 
3. 3.02 
 
100.83 
 
       
     Table 37 : Results of Assay  of PNP       
S.No
. 
Label 
claim 
Amount 
present 
(mg) 
 
%purity 
 
SD 
 
RSD 
1.  
40mg 
40.0 
 
100.01 
 
± 0.4714 
 
0.0046 
2. 40.0 
 
100.00 
3. 40.4 
 
101.00 
 
VALIDATION OF THE PROPOSED RP –HPLC METHOD 
 ACCURACY: (Mousumi Kar., et al., 2009) 
The accuracy of the developed method was determined by performing 
recovery studies using the standard addition technique. A known amount of the 
standard drugs were added to the respective samples and the chromatogram was 
Department of Pharmaceutical Chemistry Page 121 
 
recorded for the same. The recovery studies were performed on 50% spiked samples 
and injected in duplicate. The analysis was performed thrice. The results of the 
recovery are shown in table-38 and 39. The percentage recovery was found lie 
between 98.89 and 100.00 % and 99.50 and 101% for PNP.  The results of the 
recovery analysis suggest that the developed method has no interference by the 
sample matrix. 
 
Table 38: Results of recovery studies of CNP  
Ex
pe
ct
ed
 
 
%
 
R
ec
o
v
er
y 
Amount 
added 
(mg) Total 
amount 
assayed 
in mg 
Amount 
Recovered 
in mg 
Assessed 
 % 
Recovery 
% 
Recovery 
 
SD RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
50% 3 1.5 
 
4.45 
 
1.41 47.10 98.89 
±0.4545 0.0045 
 
4.50 
 
1.46 48.76 100.00 
4.47 
 
1.43 47.93 99.44 
 
 
 
 
Department of Pharmaceutical Chemistry Page 122 
 
Table 39: Results of recovery studies of PNP  
Ex
pe
ct
ed
 
%
 
R
ec
o
v
er
y 
Amount 
added 
(mg) Total 
amount 
assayed 
in mg* 
Amount 
Recovered 
in mg 
Assessed 
% 
Recovery 
% 
Recovery 
 
SD RSD 
Sa
m
pl
e 
St
a
n
da
rd
 
50
% 40 20 
 
60.40 
 
 
20.4 51 100.66 
0.6937 0.0069 
 
60.69 
 
20.7 51.73 101.15 
 
59.70 
 
19.7 49.24 99.50 
 
Specificity (Lokesh Singh., et al., (2011)  
            The specificity test of the proposed method demonstrated that the excipients 
from tablets do not interfere in the drug peak. Furthermore, well shaped peaks 
indicate the specificity of the method. Better resolution was found for the drug peak 
with no interference proved that the method was found to be selective to the drug. 
Precision 
The precision of the developed method was assessed by performing the 
analysis thrice which is tabulated in table-35 and 36 
The LOD and LOQ for CNP and PNP were predicted based on the parameters of 
standard error of estimate and slope, calculated from linearity of the 
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SUMMARY AND CONCLUSION 
 Simple, Precise, rapid and accurate methods were developed for the 
estimation of Cinitapride and Pantoprazole in bulk and in dosage form. The methods 
are   
1. UV Spectroscopic method 
2. Visible Spectroscopic method   
3. RP-HPLC method. 
 The UV spectrophotometric method makes use the solubility of CNP and 
PNP in methanol. The λmax of CNP being 262nm and that of PNP is 290nm in 
methanol. The bulk drug CNP obeyed Beer’s law at 4-20µg/mL and PNP at 5-
30µg/mL. The correlation coefficient was found to be 1 for both the drugs. The 
dosage form of the drugs was quantified by the following three methods. 
 Method A involves standard absorbance method. The absorbance of both 
standard and sample were used to calculate the amount of the analyte. The recovery 
studies were performed by the standard addition technique at three spiked levels. The  
RSD proves the reproducibility of the method and thus the precision of the 
developed method.  
 Method B involves determination of AUC for both standard and sample 
spectra obtained in Method A between two selected wavelength.The correlation 
coefficient was found to be 0.9990 for both CNP andPNP. The sample concentration 
and the percentage recovery concentration were arrived by interpolation on 
calibration chart of AUC vs Concentration for both CNP and PNP. The percentage 
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purity was determined to be 99 to 101% and RSD <1 which was within the limit. 
Thus the method is said to be precise. The recovery percentage was found to be 98 to 
102% which proves no interference by the sample matrix.  
 Method C involves the derivatisation of the zero order spectra to second 
order spectra. The amplitude of the negative maxima at 262nm for CNP and 290nm 
for PNP were used to determine the amount of analytes present. The recovery spectra 
were also derivatized and used. 
 The visible spectrophotometric method involve two methods each for CNP 
and PNP.Initially for CNP, both the methods involves diazotization of the primary 
aromatic amino group and  coupling of the diazotized CNP with  ethyl aceto acetate 
(EAA) coupling with acetyl acetone (AAC) to form a diazo couple or orange red 
colored dye. The order of addition of the reagents, strength and volume of the 
reagents were optimized. Method A follows Beer’s law at 10-60µg/mL and method 
B at 10-50µg/mL.  
 For PNP both the methods initially involve oxidation to its sulfone analogue 
by the insitu liberation of excess bromine (Potassium bromate-bromide with 
hydrochloric acid).  The excess bromine oxidizes ferrous ammonium sulphate to 
ferric ammonium sulphate. Method A involves complexation of the excess FAS to 
ferroin using 1,10 phenanthroline which has a λmax at 510nm. Method B involves 
complexation of the excess ferrous ammonium sulphate to ferric thiocyanate by 
ammonium thiocyanate which shows λmax at 479nm. Method A obeys Beer’s law at 
1.2 to 5.4 µg/mL and method B at 0.4 to 2.4 µg/mL. The reagents and the conditions 
of the reaction were optimized for both the methods. The respective optimized 
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procedure was adopted for the assay, precision studies and recovery studies for both 
CNP and PNP. The precision result showed RSD<1 for all the methods. Thus the 
method developed are said to be precise. The results of the recovery studies reveal 
that the developed method showed no interference with sample matrix. Thus the 
above devised visible methods are accurate. 
 RP-HPLC method uses mobile phase containing acetonitrile: methanol: 
phosphate buffer in the ratio of 40:20:40%v/v. The chromatographic conditions were 
optimized and were found common for both CNP and PNP. CNP showed Rt at 6.5 
minutes and PNP at 3.5 minutes.  The linearity was assessed by the correlation 
coefficient equal to 1. The assay, precision and recovery studies were performed. 
The assay percentage results were subjected to repeatability studies for thrice and 
found to be precise. The results of the recovery studies showed that the method was 
devoid of interference by the sample matrix. 
 All the methods have shown good  linearity, precision and accuracy. The low 
% RSD values in recovery studies for all the above methods indicate that there is no 
interference due to excipients used in the formulations. Hence it is concluded that 
the developed UV – Visible and RP-HPLC methods were found to be simple, 
precise, accurate and rapid methods for the analysis of Cinitapride and 
Pantoprazole in its pure form and in its pharmaceutical dosage formulation. 
Thus, all the above adopted methods can be effectively used for the routine 
analysis of Cinitapride and Pantoprazole in pharmaceutical dosage form.  
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